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ABSTRACT 
Orthopaedic implants enable the restitution of locomotor function and improve 
the quality of life of many people. However, biomaterial-associated infection may 
occur due to the propensity of microorganisms to adhere and colonize implant 
surfaces. The objective was to gain knowledge on the pathogenesis of infections 
associated with percutaneous osseointegrated implants for lower limb amputation 
prostheses. The aims were to design in vitro methods for the evaluation of 
antimicrobial surface properties, evaluate a novel method for biofilm-
susceptibility testing and characterising virulence factors in bacterial isolates from 
patients with implant-associated osteomyelitis, and to investigate extracellular 
vesicle (EV)-host cell and EV-bacterial cell interactions. 
      Results demonstrated that several methods, tailored to the specific surface 
modification and antimicrobial mode of action, should be applied to provide 
complementary information when evaluating the prophylactic and treatment 
effects of antimicrobial surfaces on planktonic and biofilm bacteria. The majority 
of clinical isolates of Staphylococcus spp. and Enterococcus spp. causing osteomyelitis 
were biofilm producers that required higher antimicrobial concentrations 
compared with non-producers. The biofilm susceptibility testing method may be 
useful to guide antimicrobial treatment decisions in orthopaedic implant-
associated infection. All staphylococcal strains were able to produce EVs in vitro. 
A significantly higher level of cytotoxicity was induced in THP-1 monocytes by 
EVs compared with unstimulated controls. THP-1 cells internalised EVs and 
secreted proinflammatory cytokines to a greater degree than controls. Sub-
inhibitory concentrations of gentamycin increased secretion of EVs and their 
protein content in S. epidermidis. EVs may play a role as survival factors by 
modulating cell growth and adherence to surfaces. 
      In conclusion, isolates from implant-associated infection reveal multiple 
virulence traits relevant for understanding and treating these infections. This 
thesis proposes EVs as a novel pathogenic mechanism of biomaterial-associated 
infection, requiring further research focus.  
Keywords: osseointegration, amputation prosthesis, implant-associated infection, 
biofilm, staphylococci, extracellular vesicles, host defence, cytokines, cell death 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Ortopediska implantat används i allt större utsträckning och har förbättrat 
livskvalitén för många människor med skador och sjukdomar i skelett, leder och 
muskulatur. Infektion i anslutning till insatta implantat utgör en allvarlig 
komplikation. En bidragande orsak till detta är att den främmande ytan möjliggör 
att bakterier under vissa förhållanden kan slå sig ner på ytan, föröka sig och bilda 
en så kallad biofilm. En motverkande kraft är om implantatet eller protesen 
integreras i vävnaden. Exempel på detta är om implantatet osseointegreras dvs 
växer samman med skelettet. Behandlingen med hudpenetrerande benförankrade 
proteser för lårbensamputerade har goda kliniska resultat med förbättrad rörlighet 
och livskvalitet. Tyvärr drabbas dessa patienter ibland av infektion i anslutning till 
den delen av implantatet som sitter i lårbenet. Mekanismer för hur sådan infektion 
uppkommer är inte kända. Det övergripande syftet med avhandlingen var att 
studera olika aspekter bakom sådan infektion. Delmålen var att designa in vitro 
metoder för utvärdering av antimikrobiella implantatytor, utvärdera en ny 
kombination av metoder för att mäta biofilmers motståndskraft mot antibiotika, 
karakterisera bakteriestammar isolerade från implantatrelaterad beninfektion med 
avseende på olika virulensfaktorer samt att undersöka interaktioner mellan 
extracellulära vesiklar (EVs) frisatta från stafylokocker och kroppens 
försvarsceller samt mellan EVs och bakterier. 
Resultaten visar att vid utvärdering av antimikrobiella ytor bör flera testmetoder 
appliceras i syfte att få komplementär information. Kliniska isolat av 
Stafylokocker och Enterokocker visade olika grad av biofilmproduktionsförmåga 
in vitro med kraftigt förhöjd motståndskraft mot antibiotika. Vidare kunde alla 
Stafylokocker bilda EVs in vitro och en ökning av celldöd av THP-1 celler kunde 
påvisas när de behandlades med EVs jämfört med kontroll. EVs aktiverade THP-
1 cellerna genom NF-kB och internaliserades i en del av cellerna. THP-1 cellerna 
utsöndrade proinflammatoriska cytokiner i större utsträckning jämfört med 
kontrollförhållanden. EVs utsöndrades av S. epidermidis under antibiotikapåverkan 
vilket ändrade dess proteinmängdsinnehåll och storlek. Dessutom visades att EVs 
påverkar bakterietillväxt och vidhäftande till ytor.   
Sammanfattningsvis visar avhandlingen att bakterieisolat från djupa 
implantatassocierade infektioner uppvisar flera virulensegenskaper, inklusive 
biofilmsbildande förmåga, motståndskraft mot antibiotika samt frisättning av 
EVs som i sin tur påverkar bakteriers adhesion och tillväxt samt försvarscellers 
frisättning av cytokiner och celldöd. Denna kunskap kan användas i arbetet att 
förebygga, diagnostisera och behandla implantatrelaterade infektioner.  
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 1 
1 INTRODUCTION 
1.1 Orthopaedic implants  
Implanted medical devices have revolutionised the treatment of musculoskeletal 
disorders. Today, approximately one million total-hip and total-knee replacement 
procedures are performed each year in the United States.2 In Sweden, in 2017, 
18,148 total-hip replacements and 14,976 primary knee replacements were 
performed, increasing the numbers from the preceding year.3,4 Globally, the 
number of orthopaedic implants placed every year will continue to increase due 
to an increasingly ageing population, improved implant technology and improved 
surgical techniques.5 The challenging and emerging part of implanting foreign 
materials are adverse tissue reactions and infections. These challenges force the 
research field of constantly improving different aspects of the implants such as 
choice of materials and surface properties. Other important aspects are preventive 
measures against infections since implanted foreign materials are more susceptible 
to bacterial colonisation due to locally compromised host defence. Rapid 
detection of implant associated infections is crucial because delaying treatment 
may result in implant loss.  
1.2 Osseointegration 
The ability of an implant to integrate with bone is called osseointegration. The 
discovery of osseointegration was made by P. I. Brånemark in 1952, when a 
titanium chamber was used in an in vivo rabbit model of bone marrow circulation.6 
The integration of an implant in the bone tissue provides biomechanical stability 
and enables load bearing. The dental implant was the first application of 
osseointegration and it has been used successfully in clinical practice for more 
than 40 years.7-9 Other applications based on osseointegration include bone-
anchored hearing aids,10,11 craniofacial prostheses12 and bone-anchored 
percutaneous implants for amputation treatment.  
1.3 Percutaneous orthopaedic implants 
Based on a technology similar to that for dental implants, the bone-anchored 
percutaneous implant for amputation treatment was introduced at Sahlgrenska 
University Hospital in the 1990s. The treatment protocol, OPRA 
(Osseointegrated Prostheses for the Rehabilitation of Amputees), was established 
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in 1999 by Rickard Brånemark and co-workers (Figure 1).13 It consists of two 
separate surgical procedures. In the first surgery, the bone-implanted part, the 
titanium fixture, is inserted into the marrow cavity in the residual bone and the 
skin is re-sealed. Six months of healing without loading follow allow the fixture 
to integrate with bone tissue. During the second surgery, distal muscles are cut 
and sutured to the periosteum, leaving the protruded bone covered by a skin flap 
(trimmed of subcutaneous fat), which is attached to the end of the bone. The 
abutment is inserted through the skin, press-fit inserted into the fixture and 
secured with an abutment screw. After the second surgery, the rehabilitation 
entails a gradual increase of the load on the implant. Thereafter, the abutment 
provides an attachment site for an external prosthesis.  
 
The prerequisite for the long-term function of the implant is osseointegration 
with no fibrous tissue encapsulation. The osseointegration of the implant 
prevents micro-motion and wear particle debris that may lead to implant 
loosening.14 Follow-up studies reveal advantages in daily life offered by the OPRA 
system compared with a conventional socket prosthesis.13,15,16 The conventional 
method of attaching the prosthesis to the limb is via a socket, which suspends the 
prosthesis from the stump by compressing soft tissue. Discomfort due to the 
socket, experienced as sores, rashes and pain, and the unreliability of prostheses 
being securely suspended have been reported in several studies.17-21 
 
 
 
 
 
 
 
 
 
 
 
 
Apart from the OPRA system, two other percutaneous implant systems are 
clinically and commercially available: ILP (Integral Leg Prosthesis) and OPL 
(Osseointegrated Prosthetic Limb). These two systems were developed in 
Figure 1: Overview of the OPRA system (Integrum AB©) 
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Germany and Australia respectively. The ILP is a chromium-cobalt-molybdenum 
alloy implant that is inserted in bone with press fit.22 The implanted part is 
microporous and resembles cancellous bone to facilitate osseointegration. The 
external part is coated with titanium-niobium oxide to reduce soft-tissue 
adhesion. The OPL has two standard designs; one with an extramedullary head 
and one with an intramedullary head. The surface is a plasma-sprayed rough 
titanium coating where osseointegration is desired.23,24  
1.4 Wound healing  
Placing an implant, in soft tissue, for example, requires surgical implantation that 
causes tissue injury which involves cell death, the destruction of extracellular 
connective tissue components and the loss of blood vessel integrity.25 
Instantaneously, the process of wound healing begins; it consists of four 
overlapping series of events: haemostasis, inflammation, proliferation and 
remodelling.26,27  
 
Platelets from damaged blood vessels come into contact with and adhere to 
collagen fibres that are exposed due to the tissue injury. Platelets are activated and 
this triggers the degranulation of platelets that release cytokines, growth factors 
and clotting factors. The coagulation cascade takes place, resulting in platelet 
aggregation and fibrin clot formation at the injury site that serves as a temporary 
barrier. The blood clot that forms re-establishes haemostasis by protecting the 
exposed wound site and provides a matrix for inflammatory and other cells to 
attach to during the wound healing process. 
 
The growth factors and cytokines initially released by the platelets recruit 
inflammatory cells, such as neutrophils and monocytes, to the wound site. 
Neutrophils migrate through the blood vessel and are one of the first 
inflammatory cells to arrive at the site, with the mission of phagocytosing 
microorganisms and foreign particles. When their task is completed (typically 
within hours to days), the neutrophils undergo apoptosis. Monocytes are attracted 
to the wound and become activated macrophages that will release various 
cytokines and growth factors which initiate the formation of granulation tissue 
and they phagocytose the apoptotic neutrophils. Macrophages are the key cells in 
the transition from inflammation to repair and their presence is an indication that 
the proliferation phase has been initiated. Fibroblasts are now recruited and they 
synthesise, deposit and organise the new extracellular matrix. 
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The provisional wound matrix is replaced by granulation tissue consisting of new 
collagen fibres, other components of the extracellular matrix, macrophages, 
fibroblasts and blood vessels. The newly formed blood vessels are vital when it 
comes to sustaining the granulation tissue. Wound contraction is the complex 
interaction of cells, extracellular matrix and cytokines. Once the granulation tissue 
is formed, some fibroblasts transform into myofibroblasts and contract the 
wound. Collagen is continuously synthesised and catabolised at low rates, which 
leads to a shift from granulation tissue to scar tissue. Tissue degradation is 
controlled by proteolytic enzymes, such as matrix metalloproteins secreted by 
macrophages, epidermal cells, endothelial cells and fibroblasts.25 The scar tissue 
will never regain the initial tensile strength from before; only about 70% of the 
strength is regained.27   
1.4.1 Foreign body reaction   
Injury, blood-material interactions, formation of provisional matrix, acute 
inflammation, chronic inflammation, granulation tissue formation, foreign body 
reaction, and fibrous tissue encapsulation are host reactions following 
implantation of biomaterials.28 At the very moment of implantation, biomaterials 
are coated with host plasma proteins (predominantly fibrinogen and fibronectin); 
this coating is called the conditioning film. This conditioning film can be seen as 
the provisional matrix formation. Its composition is dependent on the 
physicochemical properties of the material and may influence inflammatory cell 
recruitment and subsequent adhesion to the material. The acute inflammation 
begins as in regular wound healing; macrophages attempt to phagocytose the 
foreign material. The macrophages begin to fuse and form multinucleated foreign 
body giant cells (FBGC) in an attempt to phagocytose the material. Foreign body 
giant cells, together with granulation tissue and new capillaries, are referred to as 
a foreign body reaction, which is the end stage of wound healing in contact with 
a biomaterial and distinguishes the healing process from the common wound 
healing process. The foreign body reaction results in fibrous tissue formation that 
encapsulates the implant.28 At this stage, the macrophages and FBGCs have 
reduced bactericidal activity, as the cells are exhausted by trying to engulf the 
foreign body, which is a sign of chronic inflammation. 
1.4.2 Skin and skin flora  
The primary role of the skin is to act as the first line of defence and it serves as a 
physical barrier to prevent the entry of pathogens and foreign substances. The 
skin shields internal organs from trauma and provides protection from ultraviolet 
 5 
irradiation when intact.29 It is colonised by commensal bacteria that work in 
symbiosis with the skin. The composition of the microbial flora depends on 
different factors, such as age, gender, environmental conditions and location.29 
Staphylococcus epidermidis and other coagulase-negative staphylococci are the most 
abundant microbial skin colonisers. Other microorganisms present are 
Corynebacterium, Propionibacterium and Brevibacterium, as well as different fungal 
species.29,30 
The skin has to be intact in order to act as a barrier. If the skin is damaged, the 
immediate process of wound healing and closure begins. The permanent 
breaching of the skin may cause the down-growth of the epithelium,31 the 
keratinisation of the epidermis and the presence of a granulation ring32 and there 
is constant ongoing inflammation at the site. Percutaneous orthopaedic implants 
breaching the skin introduce a potential pathway for microorganisms to enter the 
body in the junction between tissue, implant and the external environment.  
Loading of the system creates micro-motions between the skin and abutment 
which may contribute to the formation of the granulation ring.33  
1.5 Implant-associated infections  
Implant-associated infections are one of the main causes of the failure of 
implanted devices and account for at least 50% of all health care-associated 
infections.34 In addition, these infections are difficult to diagnose and treat.35 The 
infection may occur at different time points postoperatively: early (≤3 months), 
delayed (3-24 months), or late infection (>24 months).36 Early infections are often 
initiated during surgery, whereas late infections usually have an haematogenous 
origin. For acute infections, the causative organism is often a virulent 
microorganism such as Staphylococcus aureus. The ability to prime oxidative 
response and influence apoptosis in neutrophils differed between S. aureus and S. 
epidermidis.37 Staphylococcus aureus primed oxidative response and induced apoptosis, 
whereas S. epidermidis did not and even protected neutrophils against apoptosis. In 
addition, limited induced inflammatory response was observed when S. epidermidis 
adhered to surface which suggesting that S. epidermidis is involved in less acute 
clinical situation involving an implant surface.38 Infection occurs when a bacterial 
inoculum reaches critical size and overcomes the local host defence. Delayed or 
late infections are usually caused by less virulent, opportunistic microorganisms 
such as Staphylococcus epidermidis and Propionibacterium acnes. The clinical signs and 
symptoms are implant loosening and persistent pain.  
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It may be challenging to distinguish between aseptic implant loosening of an 
implant from septic loosening caused by a low-virulent microorganism such as S. 
epidermidis.39 The symptoms are similar, it may be hard to culture the bacteria and, 
there is a risk of contaminations of commensal microbes when sampling.40 
Histopathological analysis of Polymorphonuclear cells (PMN) infiltration in 
periprosthetic tissue was concluded to be the best method to distinguish between 
aseptic and septic loosening of hip prostheses.41 In Sweden, during 1999 - 2017, 
revisions due to aseptic loosening of total-hip prostheses accounted for 57.5%.3  
1.5.1 Osteomyelitis  
Osteomyelitis can be described as microorganisms colonising bone tissue in 
association with inflammation and bone destruction.42 The features of 
osteomyelitis, such as occurrence, type, severity and clinical prognosis, depend on 
the pathogen and its virulence, as well as the properties of the host.43 Damage to 
the bone matrix and the destruction of the vasculature are observed as the 
infection spreads to surrounding soft tissues. Sequestra, sections of dead bone, 
may form and detach to form separate infectious islands. Due to the lack of 
vasculature, the sequestra are protected from immune cells and antimicrobials and 
this may lead to the chronic persistence of the infection.44,45 The presence of an 
implant can cause chronic osteomyelitis, which often leads to the removal of the 
implant. There are several host cytokines that are important in the pathogenesis 
of osteomyelitis that are induced by staphylococcal infection in bone. The main 
inflammatory cytokines involved are tumour necrosis factor a (TNF-a), 
interleukin 1b (IL-1b) and interleukin 6 (IL-6). These cytokines play an important 
role in bone remodelling. The three cytokines stimulate the proliferation and 
differentiation of osteoclast progenitor cells to mature osteoclasts and they 
stimulate bone resorption.44 The bacteria themselves also interact directly with 
bone cells. The internalisation of S. aureus in osteoblasts contributes to the 
pathogenesis of osteomyelitis, since the internalisation provides protection for the 
microorganisms from the host defence, as well as antimicrobial agents. In 
addition, there have been reports of intracellular persistence via the formation of 
small colony variant phenotypes that form due to adaptation and contribute to 
the persistence of antimicrobial tratement.46 Ten years after implantation, the 
prevalence of osteomyelitis associated with percutaneous orthopaedic implants is 
20%.47 The two-year risk of implant-related osteomyelitis and implant removal 
due to septic causes in these femoral osseointegration patients is approximately 
8% and 2%, respectively.13  
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1.5.2 Race for the surface   
The presence of a foreign body causes the local depletion of the immune defence 
and lowers the threshold for microbial infection (it requires an at least 10,000 
times lower infectious dose of the microorganism).48 The instantaneous coating 
of an implant surface by host proteins provides an optimal substrate for microbial 
adherence and this is thought to be a critical factor for the development of implant 
infection. Bacterial adherence can be divided into two stages; primary unspecific 
reversible attachment and specific irreversible attachment.49 The physicochemical 
properties, atomic structure and composition of the surface play an important 
role in determining which plasma proteins adhere to the surface and eventually 
which, the host cells or bacteria, will be able to adhere first and win the race for 
the surface colonising the implant.49 
1.5.3 Diagnosis of infection and identification of causative organism  
There is not one test that provides a full picture of the infection related to an 
implant. Instead, different clinical signs and symptoms, together with blood tests, 
radiography, bone scans and microbiological cultures, are able to provide an 
accurate diagnosis.50 However, there are international definitions regarding 
diagnostic criteria and therapeutic strategies for periprosthetic joint infections 
(PJI).51 A test for clinical diagnosis need to have the required performance 
indicators such as sensitivity and specificity. Sensitivity and specificity express the 
proportion of patients with a certain disease and without a certain disease, 
respectively, that are correctly identified in the test. 
Implant-associated infections may be difficult to diagnose, as they are often 
caused by persistent biofilm-producing microorganisms that can escape routine 
diagnostics. When there is a suspicion of infection, the white blood cell (WBC) 
count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels 
are usually measured. ESR and CRP are suggested as criteria for the definition of 
periprosthetic joint infections.51 The CRP will be elevated directly after surgery 
and will regularly decline to normal levels after a few weeks. It is therefore 
important to measure the CRP at different time points. However, C-reactive 
protein measurement is not a sensitive test for chronic inflammation caused by 
low-virulence, biofilm-producing microorganisms. Approximately 4% of 
periprosthetic joint infections (PJI) in the hip and knee have a normal ESR and 
CRP in chronic infections.52 Histopathological examinations of tissue biopsies 
taken adjacent to the implant or the implant itself are useful when diagnosing the 
infection. X-rays are used to detect implant loosening and abscesses. Levels of 
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interleukin 1 (IL-1) and IL-6 in synovial fluid has been shown to differentiate 
between patients with periprosthetic infection from patients with aseptic 
loosening.53,54  
Intraoperative tissue samples sent for microbiological cultures are the most 
accurate specimens for this purpose. Because of their high sensitivity, they 
represent one of the most reliable methods for diagnosing implant-associated 
infections. However, the combination of use of several laboratory and 
histopathology markers of inflammation creates a better platform for 
distinguishing between septic and aseptic loosening of prothesis.41  
 
Antimicrobial treatment before sampling, delays in sending the specimens to the 
laboratory, no anaerobe cultures, an inappropriate culture medium or short 
culture times, contamination, and sending swabs instead of biopsies may 
jeopardise the ability to isolate the microorganism.36 The detection of a 
microorganism can be enhanced using molecular techniques, such as polymerase 
chain reaction (PCR), but the method is extremely sensitive that it may provide 
false-positive results due to sample contamination (e.g. skin flora). In addition, 
PCR does not distinguish between live or dead bacteria or provide the 
antimicrobial susceptibility of the pathogen.40 Matrix assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) can 
be used for the rapid identification of bacterial species.55 Alpha-defensin, a 
defensin peptide, is a biomarker that has shown great potential for the diagnosis 
of PJI.56,57 The levels of alpha-defensin are measured from samples of synovial 
fluid.  
Table 1: List of different tests used in the diagnosis of orthopaedic implant infections. Sensitivity 
and specificity shown in %. Table adapted from Widmer 2001.50 
Test Sensitivity Specificity Ref 
Blood leukocyte count 75-100 98.9-100 58 
C-reactive protein 58.3-100 90.3-100 58,59 
Serum erythrocyte sedimentation rate 16.7-50 90.3-100 58,59 
IL-6 40-95 80-87 60 
Culture of intraoperative tissue  88.2-100 86-100 50,61 
Culture of sonicated implant 94.1 42.8 61 
Synovial-fluid leukocyte 94 88 62,63 
Histopathology 25-100 >95 41,50,64 
Plain radiograph 14 70 65 
Alfa-defensin 97.1-97 96.6-97 66,67 
PCR 86 91 68 
MALDI-TOF MS 95 84 55 
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1.5.4 Treatments  
Implant-associated infections caused by biofilm-forming microorganisms often 
require long-term antibiotic treatment and combinations of antibiotics. The 
properties of an antimicrobial agent for this purpose should include having a 
bactericidal effect on surface-adhering, slow-growing and biofilm-producing 
microorganisms.69 Rifampin is a potent antibiotic against staphylococci with a 
bactericidal mode of action, as it inhibits bacterial RNA synthesis. Rifampin must 
always be combined with another antimicrobial in order to prevent resistance in 
staphylococci.70 Algorithms to aid when choosing treatment determining which 
diagnostic path to take have been developed.36,71 Treatment failures will in worst 
cases lead to implant removal. 
1.6 Pathogenesis of orthopaedic implant infections 
To establish an infection, bacteria have to orchestrate the expression of several 
virulence factors that determine the pathogenicity. There are different alternative 
pathways, to cause either a highly virulent, acute infection or a low-virulence but 
persistent chronic infection, depending on the infecting bacterial species, site of 
infection and characteristics of the host defence.  
1.6.1 Routes of infection for percutaneous orthopaedic implants 
There are different routes for microorganisms to enter the body and finally reach 
the implant site. For percutaneous orthopaedic implants, the protective skin 
barrier is permanently breached and is therefore vulnerable to microbiological 
entrance. Staphylococcus aureus, coagulase-negative staphylococci (CoNS) various 
groups of streptococci, Enterococcus faecalis and Enterobacter were found to 
colonise the abutment at the skin-penetrating site in 27 of 30 patients, but only 
one of these patients had a definite diagnosis of deep infection.32 Other potential 
pathways of infection are contamination during surgery and haematogenous 
spread.42  
1.6.2 Infectious agents 
The main microorganisms that cause infections associated with orthopaedic 
implants are the gram-positive bacteria S. aureus, S. epidermidis and less frequently 
Propionibacterium acnes, which take advantage of the weakening of the body’s 
defence near the implant surface. Other microorganisms that often appear in late 
infections are streptococci and enterococci.72 Staphylococci account for about 
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66% of biomaterial-associated infections.73 Staphylococcus aureus and S. epidermidis 
are the most commonly found isolates from percutaneous bone-anchored 
amputation prostheses, hearing aids infections and in infected knee arthroplasty 
according to clinical studies.32,74,75 
Staphylococcus aureus  
Staphylococcus aureus is a highly virulent microorganism with an arsenal of toxins 
and factors promoting evasion from the host. The cell wall is composed of a single 
lipid membrane surrounded by a thick layer of peptidoglycan, teichoic acid. The 
teichoic acids exist in two major forms, lipoteichoic acid (LTA) linked to the cell 
membrane and wall teichoic acids linked to the peptidoglycan. The peptidoglycan 
chains contribute to the rigidity of the cell wall and protects the bacteria from 
osmotic lysis and the teichoic acid provide a negative net charge of the bacterial 
cell.76 The ability to adhere to a surface is one of the many virulence factors of S. 
aureus. The key components for successful adherence to the surface are several 
microbial surface components recognising adhesive matrix molecules 
(MSCRAMM) that facilitate the attachment to host matrix molecules such as 
fibrinogen, fibronectin and collagen.77 The conditioning film formed at the 
implant surface serves as a substrate for S. aureus adherence mediated by 
MSCRAMM.78 One of the MSCRAMMs present on the surface of S. aureus is 
clumping factor A (ClfA) that is the dominant fibrinogen-binding protein. Genes 
encoding for wall-anchored adhesins fibronectin binding proteins, fnbA and fnbB, 
have been reported to be present in 98% and 99% of clinical S. aureus isolates in 
orthopaedic implant-associated infections.79 The possession of different virulence 
factors such as cell wall-anchored proteins and capsule polysaccharides promotes 
the evasion of S. aureus from the host defence (Figure 2).80 Protein A is a cell wall-
anchored protein that binds to the Fc region of IgG. The binding results in 
coating the surface of the bacterial cell with IgG molecules that are oriented in 
the wrong direction and are therefore functionally impaired. As a result, 
opsonisation does not take place and the bacteria are therefore not able to be 
recognised by the neutrophils or to activate the complement system.81 Preventing 
opsonisation is a way for S. aureus to prevent engulfment, which is important in 
the success of infection.81 Most S. aureus strains express a microcapsule layer 
around the cell that contributes to the resistance to phagocytosis. Cell-wall-
anchored proteins interact with integrins and promote the invasion of non-
phagocytic host cells. When internalised, the bacteria are able to cause host cell 
apoptosis or necrosis, or they can enter a semi-dormant state called small colony 
variants inside the cells.82 Staphylococcus aureus also possesses the ability to promote 
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evasion via exotoxins, invade host cells or degrade components of the 
extracellular matrix. A group of enzymes and cytotoxins which includes 
hemolysins (alfa, beta, gamma, and delta), nucleases, proteases, lipases, 
hyaluronidase, and collagenase are secreted by nearly all S. aureus strains.83 It has 
been shown that a-hemolysin (hla) and leukotoxin AB (LukAB) are important in 
biofilm persistence by promoting macrophage dysfunction and cell death.80,84  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staphylococcus epidermidis  
Staphylococcus epidermidis is much less virulent than S. aureus, with the ability to form 
a biofilm as its main virulence factor.85 Staphylococcus epidermidis lacks secreted 
toxins in contrast to S. aureus.86 However, S. epidermidis produces phenol-soluble 
modulins (PSMs) that can induce proinflammatory cytokines and have a cytolytic 
effect on neutrophils.30,86 MSCRAMMs of S. epidermidis binds to host fibrinogen 
(SdrG), fibronectin (Embp), vitronectin (AtlE, Aae), and collagen (GehD).86-88 
Proteins involved in bacterial accumulations are accumulation-associated protein 
(Aap), extracellular matrix-binding protein (Embp), biofilm-associated protein 
(Bap).89 The exopolymer poly-gglutamic acid (PGA) is important for S. epidermidis 
resistance to neutrophil phagocytosis and antimicrobial peptides.90 
 
Figure 2: Cell wall components of Staphylococcus aureus. Figure adapted from 
Lowy1 
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Enterococci 
Enterococci are important nosocomial pathogens in the intestinal tract of humans 
and animals. Clinically, they pose a growing problem due to their high 
antimicrobial resistance, especially vancomycin resistance. Enterococcal biofilms 
have been observed in a number of implant-associated infections91 and is an 
important virulence factor of enterococci. One of the quorum-sensing systems is 
fsrABC and it regulates the biofilm-associated genes and operons (including 
bopABCD, ebpABC, gelE and sprE).92 E. faecalis biofilm cells revealed 101 
differentially regulated genes compared with planktonic cells.93 
Quorum-sensing system 
Staphylococci have developed a density-dependent, quorum-sensing system that 
enables cell-cell communication. Quorum sensing is a way for bacteria to regulate 
pathways in order to control gene expression, to detect and respond to changes 
in the environment in a large population of bacteria.94 Quorum sensing plays a 
vital role in biofilm formation and is therefore an important mechanism for 
studying infection-control strategies.95,96 The signals of quorum-sensing systems 
are small molecules called autoinducers. These autoinducers need to reach a 
certain threshold concentration in order to activate a transcription regulator 
which is achieved at high cell population densities. The agr locus consists of the 
transcriptional units RNAII and RNAIII, responsible for the expression of the 
autoinducer peptide and the control of the expression of PSMa and PSMb 
peptides respectively. Agr may influence biofilm behaviour, such as attachment, 
dispersal and the chronic nature of biofilm-associated infections, by activating the 
expression of virulence determinants such as a-toxin, surface-associated 
adhesins, d-hemolysin and the autolysin AtlE.97 The autolysins, AtlA and AtlE, 
involved in cell wall turnover, cell division and cell lysis are found in S. aureus and 
S. epidermidis.98 The inhibition of agr activity leads to the increased expression of 
adhesin factors and the decreased expression of dispersal factors which may 
convert an acute infection into a chronic infection.99  
1.6.3 Staphylococcal biofilm formation  
Bacteria are able to exist in a free-floating planktonic phase or in an adhered 
biofilm phase, where the latter is the preferred mode of growth.100,101 Most 
bacteria are biofilm opportunistic; when a surface is available, they will attach to 
it and recruit other free-floating bacteria to form a complex bacterial community, 
the biofilm.102 Although the molecular mechanisms of biofilm formation depend 
on the bacterial species (there is no universal biofilm mechanism), the biofilm-
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formation process is cyclic and consists of five steps (Figure 3). In the first step, 
planktonic bacteria reversibly adhere to a surface by physicochemical interactions, 
such as van der Waals forces, hydrogen bonding, electrostatic interactions and 
hydrophobic interactions.103 In step two, adherence to the surface relies on 
bacterial adhesins (MSCRAMMs), capsule and extracellular matrix components 
that adhere to the proteins of the conditioning film formed on the surface and 
the adhesion becomes irreversible. Step three is the accumulation; intercellular 
connections are made between the bacterial cells. For S. epidermidis, polysaccharide 
intercellular adhesin (PIA), regulated by the ica operon, is expressed and it serves 
as the glue between the bacterial cells. Extracellular DNA (eDNA) has been 
shown to be important in the accumulation phase by contributing to biofilm 
stability.  
The formation of a biofilm represents a cost-effective way of living and the 
bacteria create niches in different locations in the biofilm to survive and help the 
large population. Naturally, bacteria at the bottom of the biofilm are less exposed 
to nutrients and therefore become dormant. These dormant cells (persister cells) 
have a low growth rate and are therefore less vulnerable to cell wall-active 
antibiotics.104,105  
The extracellular polymeric substances (EPS), such as polysaccharides, eDNA 
and supportive proteins secreted by the bacteria, help the bacteria to adhere to a 
surface and enables bridging between the cells. The ica operon, containing the 
genes icaA, icaB, icaC and icaD, encodes the enzyme that synthesises the PIA poly-
N-succinyl-b -1,6-glucosamine.106,107 PIA is the main polysaccharide in the biofilm 
matrix in S. aureus and S. epidermidis. The EPS maintains highly hydrated 
microenvironment, helps trapping nutrients, facilitates horizontal gene transfer 
between the bacterial cells, store energy within the biofilm, and protects them 
from immune cells.69,100,108,109 Complex networks of channels within the biofilm 
are formed to transport nutrients and waste products in and out of the biofilm. 
The channels provide accessibility to essential nutrients in even the deepest 
regions of the biofilm.110 There is a gradient of nutrients111 which can cause 
heterogeneous gene expression throughout a biofilm.112 The biofilm is able to 
respond to changing conditions by displaying variability in physiological states 
and has a powerful defence against antimicrobial agents and the host immune 
response.104 The biofilm resembles multicellular organisms which protect the 
bacteria from the host’s immune mechanism104,113 Macrophages attempting to 
engulf biofilms become frustrated macrophages. The biofilm mode creates an 
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optimal environment for the horizontal gene transfer of antimicrobial resistance 
genes by plasmid exchange between cells.104,114,115  
Step four is the maturation of the biofilm and tower-like formations are formed. 
The fifth and last step is dispersal. The bacteria may leave the biofilm when the 
shear forces overcome the tensile strength of the biofilm or when it is no longer 
profitable for the bacteria to stay due to limitations in nutrients. PSMs, controlled 
by the agr locus, cause the disruption of the biofilm matrix to form channels for 
the delivery of nutrients to deeper layers of the biofilm.116 The result of channels 
weakens the biofilm structure causing dissemination of parts of the biofilm. The 
bacteria detach and become free floating again to find another surface to attach 
to and build a new biofilm.108  
 
 
Figure 3: Schematic overview of the different stages of biofilm formation. Adapted from Otto 
200987. 
1.6.4 Biofilm antimicrobial resistance, tolerance and persistence 
Antimicrobial resistance is the inherited ability of bacteria to grow at high 
concentrations of antibiotics, preventing the interaction with its intended target, 
and it is quantified by the minimum inhibitory concentration (MIC). There are 
three broad categories of antimicrobial resistance mechanisms: (1) inactivation of 
the antimicrobial agent through enzymes; (2) mutations that eliminate the 
molecular target for the antimicrobial agent; (3) and by reducing antimicrobial 
permeability.117 One example of the first category is the staphylococcal b-
lactamase, which modifies b-lactam antibiotics through hydrolysis of the b-lactam 
ring. The opening of the b-lactam ring prevents the binding to its penicillin-
binding protein (PBP) target site. Examples of the second category are 
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modification to DNA gyrase (GyrA) resulting in quinolone resistance, 
methylation of 23s rRNA that inhibits macrolides, modification of PBP, and by 
acquiring the chromosomal gene mecA resulting in methicillin resistance.118 The 
third category mainly applies for Gram-negative bacteria, which are efficient in 
restricting the diffusion of antimicrobial agents through their outer membrane. 
The negatively charged lipopolysaccharides (LPS) in their outer membrane limits 
the entry of hydrophobic antimicrobial agents.118  
Tolerance to an antimicrobial agent is defined as the ability of a microorganism 
to survive, but neither grows nor dies, in the presence of a bactericidal 
antimicrobial agent. Tolerance mechanisms can prevent the bactericidal agent 
from using its downstream toxic effects even though the agent has bound to its 
target.  
Biofilm antimicrobial resistance may be either acquired or intrinsic. The acquired 
resistance involves horizontal gene transfer of antimicrobial resistance genes by 
plasmid exchange between cells, or by mutations. In contrast, the intrinsic 
antimicrobial resistance (or tolerance) of biofilms, is a non-heritable phenotype 
tightly connected to the biofilm mode of growth and is multifactorial. The 
mechanisms that contribute to antibiotic tolerance include: restricted 
antimicrobial diffusion in the biofilm due to the EPS, bacterially-altered 
microenvironments, such as pH differences, which may antagonise antibiotic 
efficacy, and bacterial persister cells.104,119 Persister cells possess lower metabolic 
activity and are in a dormant state, which makes them less susceptible to 
antimicrobials.104,120,121 Persistence does only occur in a subpopulation of bacterial 
cells.122 One strategy of treating biofilm infections is by targeting the different 
subpopulations of bacterial cells within the biofilm.  
1.6.5 Gram-positive extracellular vesicles 
Gram-negative bacteria secrete spherical and bilayered membrane vesicles with a 
diameter of 20-300 nm, reflect the outer membrane and periplasmic 
components.123 It has been shown that they contain toxins, adhesins, enzymes, 
communication compounds, nucleic acids and pathogen-associated molecular 
patterns.124-126 These vesicles take part in cell-cell communication, killing 
competitive bacteria, delivering toxins to host cells, inactivation of antimicrobials 
by enzymatic degradation.127-130 Membrane vesicles of Gram-negative bacteria has 
also been located in the extracellular matrix of biofilm.131 Vesicles derived from 
Gram-negative bacteria have been studied for more than 50 years, but only a few 
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studies focus on vesicles from Gram-positive bacteria, due to their lack of an 
outer membrane.126 Extracellular vesicle (EVs) have been observed for several 
Gram-positive bacterial species, including S. aureus, and contain a range of cargo 
molecules, such as nucleic acids, proteins, lipids, viruses, enzymes and toxins.132,133 
Lee et al. reported the identification of 90 vesicular proteins found in S. aureus, 
where the cytoplasmic proteins were the most common, followed by extracellular 
and membrane proteins.134 Data indicated that many vesicular proteins are likely 
to be involved in facilitating the transfer of proteins to other bacteria, as well as 
eliminating any competitive organisms, cellular defence, in antibiotic resistance, 
pathological functions in systemic infections.134,135 An in vivo study performed by 
Gurung et al. has shown that S. aureus produces EVs that deliver bacterial effector 
molecules to host cells and induce morphological changes of epithelial Hep-2 cells 
leading to cell death.136 It has also been suggested that α-hemolysin is released via 
the EVs of S. aureus and delivered to human host cells.137 This indicates that EVs 
secreted from S. aureus may be associated with the development or progression of 
diseases. In addition, studies on EVs derived from S. aureus showed that they 
contained the β-lactamase protein BlaZ which confers penicillin resistance.132,138 
Recently, it was found that EVs are able to act as bridging factors in biofilms that 
produce an environment that is resistant to antibiotitcs.124 However, to our 
knowledge, no studies have been performed on S. epidermidis and its ability to 
produce EVs, as well as the role of staphylococcal EVs in medical device-related 
infections.  
1.7 Infection prevention and control strategies  
There are different strategies for the control of implant-associated infections. 
They include the use of laminar flow in operating theatres, strict rules and routines 
in the operating theatre, sterile garments, preoperative antimicrobial prophylaxis 
and improvements in postoperative care. Another aspect of infection prevention 
is controlling the surface properties of the implant. The physicochemical 
properties of the implant surface play a major role in whether the host cells or 
bacteria arrive first at the surface and colonise it.49 The research in the biomaterial 
field of engineering antimicrobial surfaces is extensive with different 
approaches.139-141  
1.7.1 Non-adhesive surfaces 
Different clinical applications require different antimicrobial approaches. One 
strategy is to create non-adhesive or bacteria-repellent surfaces preventing 
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bacteria from adhering. However, this strategy also prevents the host cells 
adhering and thereby prevents tissue integration that is crucial for orthopaedic 
implants, for example. The non-adhesive approach is applicable with contact 
lenses, urinary catheters and other temporary implant applications that do not 
require tissue integration. To achieve a non-adhesive mode of action, hydrophilic 
polymer coatings and polymer brush coatings are applied to the surface.142  
1.7.2 Tissue-integrating surfaces 
Applying the race for the surface theory, tissue-integrating surfaces have been 
developed.49 The principle for these surfaces is to attract host cells to adhere to 
the surface before the bacteria arrive. This has been accomplished by using 
arginine-glycine-aspartic acid (RGD) peptides143,144 as cell adhesion promoters for 
vascular grafts, while hydroxyapatite coatings have been used for dental and 
orthopaedic implants.145 
1.7.3 Contact-killing surfaces 
Killing the microbes as they approach the surface by direct interaction with the 
bacterial cell is achieved using a contact-killing mode of action. Silver is widely 
used for this mode of action, as it has broad-spectrum antibacterial properties. It 
has been used as an antimicrobial agent since ancient times to clean wounds and 
silver threads have been used as sutures. Nowadays, silver is used in medical 
devices such as catheters146, wound dressings147 and on stainless steel pins148. Pure 
metallic silver is inert and does not react with host tissue and does not kill bacteria 
until it is ionised, however, the exact mode of action is unknown.149 The 
advantage of silver compared with antibiotics is that it is less prone to resistance 
development150 and Gosheger et al. showed that a silver coating does not produce 
local or systemic side-effects in humans.151 However, argyria has been reported in 
patient with burn wound treated with silver-coated dressing.152 One drawback 
with the contact-killing strategy is the adhesion of host proteins (conditioning 
film) upon implantation, compromising the contact-killing mode of action.  
1.7.4  Releasing surfaces 
Antimicrobial peptides 
Antimicrobial peptides (AMPs) are small, cationic components that are part of 
the innate immune system. They play an important role in preventing bacterial 
infections and possess broad spectrum antimicrobial activity against bacteria, 
fungi, and viruses.153 AMPs act by either permeabilising microbial cell membranes 
or by translocation across the cell membrane to attack their cytoplasmic target.154 
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AMP coatings are able to make the implant surface biofilm resistant without being 
toxic to host cells. The development of antimicrobial resistance is therefore 
considered low in contrast to antibiotics.155  
Antibiotics and antiseptics 
One way of applying antimicrobials locally is by coating the implant surface with 
an antibiotic or antiseptic agent. Molecules such as triclosan, chlorhexidine and 
gentamicin have been applied to the surface and slowly release the active 
substance.150 However, problem with drug-eluting surfaces has been that they 
tend to be fragile and it is hard to achieve the release over a longer period of time. 
Many of the attempts to create drug-releasing surface have not yet reached clinical 
use.150 
1.8 Diagnostic tools to guide treatment  
1.8.1 In vitro model testing  
MIC 
Routine antimicrobial susceptibility in clinical laboratories is determined by disk 
diffusion tests. Another method is (MIC) determination which requires serial 
liquid broth dilutions or an antibiotic gradient strip test. These tests rely on 
recovered, planktonic bacteria and serve as an important method in the treatment 
of many acute infections. The antimicrobial tolerance is lost once the bacteria 
from the biofilm revert to conditions that permit planktonic growth.111 The MIC 
may therefore be misleading when testing isolated bacteria from a chronic 
implant-associated infection which may involve biofilms.  
MBEC 
The Calgary biofilm device (CBD) is a well plate with 96 identical cones attached 
to the lid of the microwell plate. The specially designed plate enables the 
formation of 96 identical biofilms on the cones when placed in wells containing 
bacterial inoculum solutions. After the desired incubation time, the cones can be 
transferred to an antimicrobial plate to determine the minimum biofilm 
eradication concentrations (MBEC).156 This method has not been evaluated for 
clinical use, but MBEC may better reflect the antimicrobial concentrations needed 
to eradicate an infection caused by biofilm-producing bacteria.  
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2 AIMS  
The main objective of this PhD thesis was to acquire a deeper knowledge of the 
pathogenesis of infections associated with percutaneous orthopaedic implants. 
The specific aims were as follows. 
1) To explore different methods that can be used to evaluate the treatment 
effects of biomaterial surfaces and to evaluate the antimicrobial 
performance of different surface treatments [Paper I] 
 
2) To design and evaluate a novel combination of the Calgary biofilm device 
and a commercial susceptibility MIC plate using strains derived from 
patients with implant-associated osteomyelitis, as well as to determine the 
strains’ biofilm formation abilities and biofilm antimicrobial susceptibility 
and to relate these properties to the clinical outcome of these patients 
[Paper II] 
 
3) To determine whether staphylococci derived from implant-associated 
osteomyelitis produce extracellular vesicles and, if so, to characterise 
them (size, concentration, protein content), and finally to evaluate the 
expression and secretion of selected cytokines and cytotoxic effects of 
extracellular vesicles in a THP-1 monocytic cell line [Paper III] 
 
4) To investigate whether sub-inhibitory concentrations of gentamicin have 
an impact on extracellular vesicle production in clinical Staphylococcus 
epidermidis and whether these vesicles influence bacterial growth and 
adhesion properties. To study whether extracellular vesicles from an 
antimicrobial resistant and biofilm-producing strain alter the phenotypic 
susceptibility and biofilm formation properties of a susceptible non-
biofilm-producing clinical strain [Paper IV] 
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3 MATERIALS AND METHODS 
In what follows, several in-vitro models were included using both reference and 
clinical strains. Experiments involving bacterial strains derived from patients with 
percutaneous orthopaedic implant infections were approved by the Regional 
Ethical Review Board in Gothenburg. 
3.1 Patients 
Bacterial strains analysed in the retrospective study presented in Paper II were 
retrieved from patients with deep infections related to percutaneous orthopaedic 
implants for amputees. The patient group included all eligible patients treated 
since the introduction of the method until the start of data retrieval. Retrieved 
samples were cultured at the Clinical Bacteriology Department (Sahlgrenska 
University Hospital, Gothenburg) and disk diffusion susceptibility testing was 
performed to determine which antimicrobial treatment to administer to the 
patients. Diagnosis, treatment and outcome information was extracted 
retrospectively from patient records. Infection was defined and graded by signs 
and symptoms of deep infection, X-ray findings and positive tissue cultures, 
according to a method previously described by Tillander et al.157  
An outcome score (0-3) was used to group the patients according to the number 
of complications (relapse, re-infection and implant extraction). Treatment failure 
was defined as either a relapse within the study period or implant extraction due 
to unresponsiveness to administered antimicrobial treatment. Re-infection, 
caused by different microorganisms after completed antimicrobial treatment with 
clinical resolution, was not regarded as treatment failure. The demographics are 
presented in Table 2. 
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Table 2: Demographics and clinical outcome. 
 
 a(+  signs/symptoms + X-ray + cultures#), b(+ signs/symptoms ± X-ray + cultures#) and c(+ 
signs/symptoms ± X-ray – cultures#) 
#Two or more positive bone and/or bone marrow cultures out of five, yielding indistinguishable 
bacteria in routine identification157 
3.2 Bacterial cultures 
3.2.1 Bacterial strains 
A common reference strain of Staphylococcus aureus (ATCC 25923; Culture 
Collection, University of Gothenburg) [Papers I-IV] was originally a clinical 
isolate from Seattle 1945. Staphylococcus aureus (ATCC 29213; Culture Collection, 
University of Gothenburg) [Papers I-II, IV] originally obtained from a wound is 
a reference strain for staphylococci in MIC determinations. Staphylococcus aureus 
Xen29 (Caliper Life Sciences, Alameda, CA) possesses a stable copy of 
the Photorhabdus luminescens lux operon on the bacterial chromosome and has been 
used in this work for in-situ luminescence measurements [Paper I]. Staphylococcus 
epidermidis (ATCC 35984; Culture Collection, University of Gothenburg) [Papers 
I-IV] is a biofilm-producing strain originally obtained from a patient with catheter 
Demographics and clinical outcome  
Number of patients 11 
Gender:  
     Male 8 
     Female 3 
Number of implants 11 
Reason for amputation:  
     Trauma 10 
     Tumour 1 
     Infection 0 
Femoral amputation level:  
     High 3 
     Mid 7 
     Low 1 
Osteomyelitis:  
     Definitea 8 
     Probableb 2 
     Possiblec 1 
Median years of age at time of diagnosis of osteomyelitis (range) 42 (22-71) 
Median time in months since implantation (range) 47 (2-143) 
Median number of months on antibiotics (range) 4 (1.5-8) 
Implant extraction due to osteomyelitis 4 
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sepsis. This strain has been used throughout this work as a reference strain for 
biofilm production and as an extracellular vesicle donor. Staphylococcus epidermidis 
(ATCC 35983; Culture Collection, University of Gothenburg) [Papers II] is a 
biofilm-producing strain originally obtained from blood and it was used in the 
study as a control strain for its moderate biofilm-production ability. Staphylococcus 
epidermidis (ATCC 12228; Culture Collection, University of Gothenburg) [Papers 
II-IV] is a non-biofilm-producing strain and it has been used as a negative control 
for biofilm production. Pseudomonas aeruginosa PAO1 (ATCC 15692; Culture 
Collection, University of Gothenburg) [Paper I] is a gram-negative strain 
originally isolated from an infected wound and it was used in this work as a 
reference strain for a disk diffusion test. Staphylococcus epidermidis DSM 18857 
(Leibnitz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures, Germany) [Paper I] was used in primary adhesion tests.  
The following strains were isolated from percutaneous implant-associated 
infections: Staphylococcus epidermidis CCUG 64518, Staphylococcus epidermidis CCUG 
64521, Staphylococcus epidermidis CCUG 64523, Staphylococcus aureus CCUG 64514, 
Staphylococcus aureus CCUG 64516, Staphylococcus aureus CCUG 64520, Staphylococcus 
aureus CCUG 64522. (Culture Collection, University of Gothenburg) [Papers II-
IV] and Enterococcus faecalis CCUG 64515, Enterococcus faecalis CCUG 64517, 
Enterococcus faecalis CCUG 64519, Enterococcus faecalis CCUG 64524, Enterococcus 
faecalis CCUG 64526 and Enterococcus faecalis CCUG 64527 (Culture Collection, 
University of Gothenburg) [Papers II]. The CoNS clinical strains were further 
characterised as S. epidermidis using the API Staph (bioMérieux SA, Marcy-l’Etoile, 
France). All the clinical strains have been characterised, with respect to biofilm 
production and antimicrobial susceptibility in both the planktonic (MIC) and 
biofilm (MBEC) state. Extracellular vesicles have been isolated from the clinical 
staphylococcal strains. All strains used in this work are listed in Table 3. 
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Table 3: List of bacterial strains used in this work. 
Species Strain ID Source In Papers Ref 
S. epidermidis CCUG 64518 Osteomyelitis II-IV This work 
S. epidermidis CCUG 64521 Osteomyelitis II-IV This work 
S. epidermidis CCUG 64523 Osteomyelitis II-IV This work 
S. aureus CCUG 64514 Osteomyelitis II-IV This work 
S. aureus CCUG 64516 Osteomyelitis II-IV This work 
S. aureus CCUG 64520 Osteomyelitis II-IV This work 
S. aureus CCUG 64522 Osteomyelitis II-IV This work 
E. faecalis CCUG 64515 Osteomyelitis II This work 
E. faecalis CCUG 64517 Osteomyelitis II This work 
E. faecalis CCUG 64519 Osteomyelitis II This work 
E. faecalis CCUG 64524 Osteomyelitis II This work 
E. faecalis CCUG 64526 Osteomyelitis II This work 
E. faecalis CCUG 64527 Osteomyelitis II This work 
S. epidermidis ATCC 35984 Catheter sepsis I-IV 158 
S. epidermidis ATCC 35983 Blood II This work 
S. epidermidis ATCC 12228 Non-infection associated 
isolate 
II-IV 159 
S. epidermidis DSM 18857 Infected central venous 
catheter 
I This work 
S. aureus ATCC 25923 Clinical infection isolate I-IV 160 
S. aureus ATCC 29213 Wound I-II, IV 161 
S. aureus Xen29 Pleural fluid isolate I 162 
P. aeruginosa PAO1 Wound I 163 
 
3.2.2 Bacterial inoculum preparations 
All the strains were stored at -80°C in freezing media containing tryptic soy broth 
(TSB) and 20% glycerol. Upon use, the strains were streaked on Luria Bertini (LB) 
agar [Paper I] or Mueller-Hinton agar [Paper II] or 5% horse blood Columbia 
agar plates [Papers I-IV] and incubated over night in humidified air at 37°C. Single 
colonies were then added to TSB [Papers I-III] or Mueller-Hinton broth (MHB) 
[Papers III-IV] until optical density (OD546 nm) of 0.25 for S. epidermidis strains, 
0.13 for S. aureus strains, 0.27 for E. faecalis and 0.26 for P. aeruginosa was reached, 
corresponding to approximately 108 CFU ´ mL-1. Inoculum suspensions between 
105-107 CFU ´ mL-1 were then prepared by diluting the OD suspensions. The 
bacterial concentrations in the inoculum suspensions were confirmed by plating 
20 µL spots of 7-12 tenfold dilutions in saline on duplicate blood agar plates and 
incubated over night for 18-20 hours.  
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3.3 Materials 
3.3.1 Substrate and coatings 
The substrate for different coatings used in Paper I was commercially available 
machined (M) titanium (Ti) grade 5 (Ti-6Al-4V) (Elos Medtech, Pinol,  Gørølse, 
Denmark). The substrates were cylindrical (Ø59 mm, thickness 2 mm, surface 
roughness Ra = 0.4 mm). M Ti is an implant material that is widely used in dental 
and orthopaedic applications and it therefore served as a control surface. 
Cathodic vacuum arc evaporation164 for a deposition time of 30 minutes was 
applied to the substrate to produce a crystalline TiO2 coating with a pronounced 
anatase phase composition. Upon UV irradiation, TiO2 has a photocatalytic 
antimicrobial mode of action. These TiO2-coated disks were denoted physical 
vapour deposition (PVD). 
The silver coating on substrates was applied using Bio-Gate (Nürnberg, 
Germany) surface treatment technology (HyProtect Coating). This coating is 
applied by a combination of chemical vapour deposition (CVD)-PVD-CVD 
process steps and results in a three-layer coating.165 Oxygen is used to initiate the 
polymerisation of the precursor monomer (hexamethyldisiloxane) in the CVD 
(chemical vapour deposition) part of the process. Silver is transferred from solid 
phase to gas phase in the PVD (physical vapour deposition) process step. The 
vapour condenses onto the substrate and forms small agglomerates. In the last 
CVD step, the silver clusters are covered with a plasma polymer layer which 
results in the complete embedment of the elemental silver in a polysiloxane 
matrix. The Ag/SiOxCy plasma polymer applied to the substrate has a contact 
killing mode of action. This test surface is referred to as Ag.  
The materials used in this work are listed in Table 4. 
3.3.2 Scanning electron microscopy (SEM) 
The coated disks were characterised by scanning electron microscopy (SEM) 
using a Zeiss 1550 scanning electron microscope, operating at 5 kV using an 
Inlens detector (Paper I). 
SEM was also used to visualise EVs derived from bacteria [Papers III-IV]. The 
EVs were deposited onto 200 mesh Cu 01700-F formvar carbon-coated grids at 
a concentration of 0.5-1 µg ´ mL-1. After one hour, the samples were fixed in 2% 
paraformaldehyde for 10 minutes, washed in PBS, post-fixed in 2.5% 
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glutaraldehyde, washed in distilled H2O and contrasted with 2% uranyl acetate for 
15 minutes. Samples were dried, Au sputter coated (~10 nm), and examined using 
SEM (Ultra 55 FEG SEM, Leo Electron Microscopy Ltd, UK) in the secondary 
electron mode, operated at 5 kV accelerating voltage and 10 mm working 
distance. 
 
 Table 4: List of materials used for antimicrobial testing in Paper I. 
 
 
3.4 Assays for antimicrobial surface evaluations 
3.4.1 Biofilm eradication 
In Paper I, S. aureus ATCC 25923 was inoculated into a CDC biofilm reactor 
CBR90 (BioSurface Technologies Corporation, Bozeman, MT) containing 500 
mL of TSB to form homogeneous biofilms under flow on TiO2-coated (PVD) 
disks and commercially available machined titanium (M Ti). The CDC reactor was 
incubated at 37°C and 130 rpm under batch conditions for 24 hours. Disks were 
rinsed and UV irradiated (20 mW ´ cm-2, 365 nm peak emission) for 0, 15 and 60 
minutes on both sides [Paper I]. 
3.4.2 Primary bacterial adhesion 
A proliferation assay [Paper I] was performed to analyse the ability of adhered 
cells to survive and proliferate on a surface. Silver (Ag) and machined titanium 
(M Ti) disks were incubated with Staphylococcus epidermidis DSM 18857 for one 
hour. Non-adhered cells were removed by rinsing and the disks were transferred 
to new well plates with minimal media and incubated for another 18 hours at 
37°C. The disks were removed and the wells, containing potential daughter cells, 
were supplemented with TSB and incubated for another 24 hours in a plate reader 
in kinetic mode and optical density at 578 nm was measured [Paper I]. 
3.4.3 Biofilm inhibition 
PVD and M Ti disks were irradiated with UV for 0, 15, 30 and 60 minutes prior 
to incubation with 105 CFU ´ mL-1 S. aureus ATCC 25923 to investigate whether 
pre-treatment would result in a reduction in adhered bacteria. The disks were then 
incubated at 37°C for 24 hours [Paper I].  
Surface Notation 
Machined titanium M Ti 
TiO2 coating PVD 
Silver coating Ag 
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The biofilm inhibitory effect of silver was also tested by incubating Ag and M Ti 
disks with 105 CFU ´ mL-1 S. aureus ATCC 25923 for 24 hours at 37°C and 150 
rpm [Paper I]. 
3.4.4 Imprint method 
Ten microlitres of 106 CFU ´ mL-1 S. aureus ATCC 25923 were deposited on PVD 
and M Ti disks before UV treatment (0, 15, 30 and 60 minutes). The disks were 
then imprinted on blood agar plates for five seconds. The disks were removed 
and the plates were incubated for 24 hours at 37°C. The imprint method was also 
applied to the Ag disks in a modified set-up. Ag and M Ti disks were incubated 
at 37°C for two hours with 30 µL of 105 CFU ´ mL-1 S. aureus ATCC 25923, after 
which the disks were imprinted on blood agar plates and incubated for 24 hours 
at 37°C [Paper I]. 
3.4.5 In situ bioluminescence  
PVD and M Ti disks with 50 µL of 106 CFU ´ mL-1 of S. aureus Xen29 in LB 
broth were UV treated for 0, 15, 30 and 60 minutes. The disks were transferred 
to a white 24-well plate and the bioluminescence was measured in a plate reader. 
The Ag disks were evaluated in a similar way. Ag and M Ti disks were placed in a 
white 24-well plate with 1 mL of 105 CFU ´ mL-1 of S. aureus Xen29 in LB broth 
and incubated at 37°C for two hours. The disks were then rinsed with saline. 
Fresh LB broth was added to the disks and they were incubated for another 48 
hours. The capability for biofilm formation in the adhered cells was analysed by 
CFU counting [Paper I]. 
3.4.6 Disk diffusion method 
S. aureus ATCC 25923, S. epidermidis ATCC 35984 and P. aeruginosa PA01 in a 
concentration of 108 CFU ´ mL-1 were spread on Mueller–Hinton agar plates to 
form confluent growth. Ag, M Ti and standard gentamicin disks were placed on 
the agar. One additional control plate of S. aureus ATCC 25923 was also tested 
for penicillin (10 iU), kanamycin (30 µg), erythromycin (15 µg) and tetracycline 
(30 µg). The plates were incubated for 18 h at 37°C prior to measuring the zone 
of inhibition [Paper I]. 
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3.5 Quantification of bacteria and biomass [Papers I-IV] 
3.5.1 Colony forming unit (CFU) counts 
The viability counting method was used to determine the number of viable cells 
in this study. A bacterial suspension of unknown concentration was tenfold 
diluted serially and plated on duplicate plates. Twenty microlitres from each 
dilution were added to duplicate blood agar plates and allowed to air dry before 
incubation (approximately 18 hours). The colonies were counted manually and 
used to estimate the concentration (CFU ´ mL-1) [Papers I-IV]. 
3.5.2 Microtiter plate assay 
The ability of a bacterium to adhere to a microtitre plate was assessed using a 
microtitre plate assay. A volume of 200 µL of 105 CFU ´ mL-1 was added to each 
well of a microtitre plate and incubated at 37°C for 24 hours. The plate was 
inverted and rinsed in three water baths to remove non-adhered bacteria. The 
remaining biofilm biomass (adherent cells and extracellular matrix) was stained 
with 0.1% crystal violet (Tris(4-(dimethylamino)phenyl)methylium chloride). The 
plate was rinsed in three water baths and the stain was eluted with 95% ethanol 
for 10-15 minutes, after which the solution was transferred to a new microtitre 
plate. The absorbance was measured at 600 nm in a plate reader.  
The cut-off value (ODc) was defined as three standard deviations (SD) above the 
mean OD of the blank (TSB):  
ODc: = average OD of blank + (3x SD of blank).  
The strains were classified as previously described by Christensen et al.166 and 
further categorised by our own biofilm biomass scoring (range 0-3) [Paper II]. 
3.5.3 Fluorescence quantification  
The biofilm production ability and cell viability of bacteria were analysed by 
fluorescence. The antimicrobial effect on planktonic bacteria was determined by 
measuring the amount of live and dead cells by fluorescence. A volume of 50 µL 
of 106 CFU ´ mL-1 of S. aureus ATCC 25923 was deposited on PVD and M Ti 
disks and then irradiated with UV for 0, 2 and 15 minutes. A working solution of 
SYTO9 (staining live cells green) and propidium iodide (PI) (staining dead cells 
red) from a FilmTracerä LIVE/DEADâ Biofilm viability kit (Invitrogen) was 
applied to each sample well and incubated in the dark for 20 minutes. The 
bacterial solution was transferred to falcon tubes and was sonicated (30 seconds), 
vortexed (one minute) and centrifuged (10,000 g, five minutes). The pellet was 
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resuspended in 1 mL of 0.9% saline solution and transferred to a black well plate. 
The fluorescence was measured in a plate reader using an excitation filter of 485 
nm and an emission filter of 520 nm [Paper I].  
In another experiment, the biofilm grown under 24 hours in a microtitre plate 
was stained with SYTO9 and PI for 30 minutes and the fluorescence intensity 
was measured in a plate reader [Paper II]. 
3.5.4 Congo red agar plate test 
The slime production of different strains was determined using the congo red 
agar plate test. Strains were streaked on blood agar plates supplemented with 0.8 
g of congo red per 1 L of brain heart infusion agar. A six-colour reference scale 
was used to determine the degree of slime production. The reference scale has 
been described before, where intensely black, black and almost black colonies are 
formed on CRA by slime-producing strains and bordeaux, red and intensely red 
colonies are formed by non-slime-producing strains167 [Paper II]. 
3.5.5 Detection of icaA and icaD genes 
Polysaccharide intercellular adhesin (PIA) is part of extracellular polymeric 
substances of staphylococcal biofilms and the synthesis of PIA is mediated by the 
icaADBC locus. The first two genes, icaA and icaD, perform a primary role in the 
exopolysaccharide synthesis.168 Cultures of the individual clinical staphylococcal 
strains and reference strains were centrifuged to pellet the bacterial cells (108 CFU 
in 1.5 mL-1). The DNA was extracted from the bacterial cells using a commercial 
Gene Elute Bacterial Genomic DNA elution kit (Sigma, St. Louis, MO, USA). A 
multiplex-PCR kit (Qiagen GmbH, Hilden, Germany) was used to amplify icaA 
and icaD with primers: 5’-TCTCTTGCAGGAGCAATCAA-icaA-Forward;   
5’-TCAGGCACTAACATCCAGCA-icaA-Reverse;  
5’-ATGGTCAAGCCCAGACAGAG-icaD- Forward;  
5’-CGTGTTTTCAACATTTAATGCAA icaD-Reverse.167 DNA bands of the 
PCR products of icaA and icaD genes were visualised with 2.2% agarose gel 
electrophoresis (Lonza, Rockland, ME, USA) [Paper II]. 
 
On the pathogenesis of infections associated with percutaneous osseointegrated orthopaedic implants 
 
30 
3.6 Susceptibility testing 
3.6.1 MBEC assay 
The Calgary biofilm device (Innovotechâ) is a commercially available plate for 
growing identical biofilms on pegs attached to a 96-well lid that fits into a 96-well 
plate containing bacterial suspensions. The biofilms were grown at 37°C and 
under shear force created by a rotary shaker incubator (150 rpm) for 24 hours.  
To determine the susceptibility of bacteria grown in biofilms, the Calgary biofilm 
device was combined with a commercial microbroth dilution plate (Sensititreâ).   
3.6.2 Antibiotic selection 
The microbroth dilution plate was custom made (Sensititreâ CML1FNUN 
TREKâ) with ten different antimicrobial agents commonly used for the clinical 
treatment of staphylococcal and enterococcal infections. The following 
antimicrobial agents were included: gentamicin (GEN), clindamycin (CLI), 
vancomycin (VAN), linezolid (LZD), ciprofloxacin (CIP), oxacillin (OXA), 
fusidic acid (FA), ampicillin (AMP), trimethoprim/sulfamethoxazole (SXT) and 
rifampin (RIF). A list of the concentrations is presented in Table 5. 
 
Table 5: List of antibiotics used in the custom-made Sensititreâ plate 
 
 
Antibiotic Abbreviation Well concentrations Group of 
antibiotics 
Gentamicin GEN 0.12-8, 128 Aminoglycosides 
Clindamycin CLI 1-128 Lincosamides 
Vancomycin VAN 0.5-32, 512 Glycopeptides and 
Glycolipopeptides 
Linezolid LZD 1-128 Oxazlodinones 
Ciprofloxacin CIP 0.5-32, 128 Fluoroquinolones 
Oxacillin OXA 1-32, 128, 512 B-lactams 
Fusidic acid FA 0.5-32, 512 Fusidic acid 
Ampicillin AMP 0.25-32, 128, 512 B-lactams 
Trimethoprim/ 
sulfamethoxazole 
SXT 1/19-32/608 Trimethoprim/ 
Sulfonamides 
Rifampin RIF 0.03-16, 128, 256 Rifamycins 
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3.7 Isolation and characterisation of extracellular vesicles [Papers 
III-IV] 
3.7.1 Isolation of EVs 
EVs from bacterial cultures were isolated and used in Paper III and Paper IV. 
One colony from overnight cultures on horse blood agar plates was inoculated in 
100 mL of TSB (Paper III) or MHB (Paper IV). The bacterial suspensions were 
incubated at 37°C for 22 hours at 125 rpm. The supernatants were made cell free 
by centrifugation (3,000 g, 20 minutes, 4°C) and were then sequentially filtered 
through 0.45 and 0.22 µm pore-size vacuum filters. The bacteria-free liquids were 
concentrated using the ÄktaFlux Benchtop System (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden) by ultrafiltration with a 100 kDa hollow-fibre membrane 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) (Paper III) and kept frozen 
until it was used. The concentrated media (Paper III) or only filtered media (Paper 
IV) was centrifuged at 16,500 g for 20 min and the supernatant was filtrated with 
0.22 µm pore-size vacuum filters (Sarstedt, Nümbrecht, Germany). The 
supernatant was ultracentrifuged at 150,000 g for three hours at 4°C in a T-647.5 
rotor (Sorvall wx Ultra series, Thermo Scientific, USA) to pellet the EVs. The 
resulting EV pellets were washed in PBS, centrifuged at 150,000 g for three hours 
at 4°C and re-suspended in PBS. Three separate batches of EVs per bacterial 
strain were isolated and stored at -80°C until further use. 
3.7.2 Nanoparticle tracking analysis 
Nanoparticle tracking analysis is a method that measures particles in the 
nanometer size range based on light microscopy and Brownian motion. Isolated 
EVs were analysed using a NanoSight LM10/LM14 instrument (NanoSight Ltd, 
Amesbury, UK). EVs were diluted in PBS, injected into the LM14 module and 
captured three times for 60 seconds, repeated three times. The recorded videos 
were then subjected to nanoparticle tracking analysis (NTA) using Nanosight 
particle tracking software 3.1 to provide nanoparticle concentrations and size 
distribution profiles (mean and standard error from 3´3 captures). This was 
performed for each EV batch for the different strains.  
3.7.3 Protein quantification 
Nanodrop, which is based on photometry, measured the protein concentration 
using the Pierce® BCA Protein Assay Kit, following the manufacturer’s 
instructions. 
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3.8 Cell culture [Paper III] 
3.8.1 THP-1 monocytic cell line and THP1-Blue™ NF-kB cells 
The human THP-1 monocytic cell line was used for a stimulation assay in Paper 
III. The monocytes were propagated in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% foetal bovine serum (FBS), 1% antibiotic-
antimycotic solution (10000 units ´ mL-1 penicillin, 10000 µg ´ mL-1 
streptomycin, and 25 µg ´ mL-1 Amphotericin B) and 0.05 mM 2-
mercaptoethanol in a 37°C humidified incubator with 5% CO2. When the cells 
reached the desired cell number, they were seeded in Nunc 24-well plates at a 
density of 500,000 cells ´ mL-1 suspended in 1 mL RPMI 1640 medium 
supplemented with 10% FBS without antibiotics. The cells were stimulated with 
S. epidermidis- or S. aureus-derived EVs at (0, 5 and 25 µg ´ mL-1). Monocytes with 
medium alone served as negative controls and LTA from S. aureus served as a 
positive control.  
THP1-Blue™ NF-kB cells were originally derived from a THP-1 monocytic cell 
line by integrating NF-kB-inducible secreted embryonic alkaline phosphatase 
(SEAP) reporter construct. The NF-kB activation is assayed by determining the 
activity of secreted embryonic alkaline phosphatase. The cells were propagated in 
RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS) and 100 
µg ´ mL-1 Normacin™. Approximately 50,000 cells ´ mL-1 suspended in 1 mL of 
RPMI 1640 medium supplemented with 10% FBS without antibiotics were 
pipetted into 96-well plates. The cells were stimulated with S. epidermidis EVs from 
strain CCUG 64521 or S. aureus EVs from strain CCUG 64516 (0, 5 and 25 µg ´ 
mL-1). The stimulation with heat-killed Listeria monocytogenes (HKLM) and 
endotoxin free sterile water was used as a positive and negative control, 
respectively. The cells were incubated in a 37°C humidified incubator with 5% 
CO2 for six, 12, and 24 hours. The QUANTI-Blue™ Solution was added to a 
new 96-well plate in a volume of 180 µL, the cell supernatants (20 µL) were added 
to the QUANTI-Blue™ Solution and incubated for one to two hours and the 
optical density was measured at 655 nm. 
3.8.2 Cell quantification 
The number of cells in medium was determined using a Nucleocounter® system 
(ChemoMetec A/S). The cell mix was loaded in Nucleocassettes™ pre-coated 
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with fluorescent propidium iodide that stains the cell nuclei and then quantified 
in the Nucleocounter®. 
3.8.3 Cell viability 
Lactate dehydrogenase (LDH) is an enzyme that leaks out from the cytoplasm 
upon cell membrane injury. Cell viability from in-vitro cultures was determined by 
measuring the lactate dehydrogenase (LDH) content of the cell-free supernatant 
LDH which catalyses the conversion between lactate and pyruvate and this 
conversion can be evaluated spectrophotometrically by measuring the reduction 
of NAD+ to NADH at 340 nm (C-laboratory, Sahlgrenska University Hospital, 
Sweden). 
3.8.4 Gene expression 
Total RNA was isolated from the samples by RNeasy Micro kit (Qiagen, Hilden, 
Germany), according to the manufacturer’s instructions. The gene panel was as 
follows: Interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), 
Interleukin-10 (IL-10), Interleukin-6 (IL-6), Toll like receptor-2 (TLR2), Toll like 
receptor-3 (TLR3), Toll like receptor-4 (TLR4), DNA damage-inducible 
transcript 4 (DDIT4), and B-cell lymphoma 2 (Bcl-2). All the samples were 
analysed in duplicate and the PCR was performed using the SFX96 real time PCR 
System (Bio-Rad Laboratories, CA, US). The relative quantification of the target 
gene expression was performed according to the standard curve method 
calculated by the ΔΔ-Cq method. 
3.8.5 Cytokine release 
Enzyme-linked immunosorbent assays (ELISA) were employed to evaluate the 
amount of secreted proteins (cytokines and chemokines) in THP-1 cell 
suspensions. The cell suspensions were centrifuged at 400 g for five minutes and 
supernatants were aliquoted and stored at -80°C until analysis. Commercial 
human ELISA kits were utilised according to the manufacturer’s instructions. The 
optical density was measured at 540 nm with a microplate reader (FLUOstar 
Omega, BMG Labtech, Germany) and translated to protein levels using standard 
curves.  
3.8.6 Confocal microscopy 
The effect of EVs on primary adhesion was studied using confocal laser-scanning 
microscopy. The clinical S. epidermidis strain CCUG 64523 was added to wells (100 
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µL) in microslide chambers at a concentration of 5 ´ 105 CFU ´ mL-1 suspended 
in MHB. EVs derived from S. epidermidis ATCC 35984 were added (100 µL) to 
the bacterial suspensions at a concentration of 100 µg ´ mL-1. MHB alone without 
EVs was added to the bacterial suspensions as a control. The slide chambers were 
incubated for five hours and 24 hours at 37°C. Non-adhered bacteria were rinsed 
with saline and adhered cells were stained with a FilmTracerä LIVE/DEADâ 
Biofilm viability kit for 20 minutes at room temperature. Excess dye was rinsed 
with saline and mounting media and objective glass was placed on slides. The 
samples were analysed with a Nikon C2 confocal laser-scanning microscope 
(CLSM, Nikon, Tokyo, Japan). 
 
The ability of THP-1 monocytic cells to internalise EVs was examined as follows: 
EVs derived from two clinical strains (S. aureus CCUG64520 and S. epidermidis 
CCUG64523) were stained with DiO dye (Molecular Probes, Eugene, OR, USA) 
for 30 minutes at 37°C. The excess dye was removed by washing using 100 kDa 
filters (Millipore, Massachusetts, USA) and PBS, according to the manufacturer’s 
instructions. Cultured THP-1 cells were stained with DiI dye (5 µL was added per 
millilitre of cell suspension of 106 cells ´ mL-1) (Molecular Probes, Eugene, OR, 
USA) and incubated for 15 minutes at 37°C. Cells were washed to remove excess 
dye and seeded in 24-well plates (5´105 cells ´ mL-1). The DiO-stained EVs were 
added to the cells (5 and 25 µg ´ mL-1) and incubated for four hours at 37°C. 
Approximately 1´105 cells were applied to microscopic slides using cytospin 
centrifugation (Shandon, Runcorn, UK). Cells were fixated with 2% 
formaldehyde for 15 minutes and washed twice in PBS before being mounted 
with Vectashield HardSet Mounting Medium with 4',6-diamidino-2-phenylindole 
(DAPI). The samples were analysed with a Nikon C2 confocal laser-scanning 
microscope (CLSM, Nikon, Tokyo, Japan). 
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4 SUMMARY OF RESULTS 
4.1 Paper I 
This work evaluates different in-vitro methods for the antimicrobial efficacy testing 
of photocatalytic TiO2 (PVD) surfaces and silver (Ag)-coated surfaces on both 
planktonic and biofilm bacterial cultures. The antimicrobial performance of the 
surfaces was also investigated. 
 
Primary bacterial adhesion: After an initial adhesion of 1 hours, no detectable growth 
of bacterial daughter cells was detected within 24 hours of culture on silver-coated 
disks. In contrast, the machined titanium (M Ti) disks showed the growth of 
daughter cells after six to seven hours. 
 
Biofilm eradication: The biofilm formed on PVD and M Ti disks after culture in a 
CDC biofilm reactor reached equal amounts of CFU (103-104 CFU ´ mL-1). 
Fewer CFUs were, however, detected after UV irradiation, on both test and 
control surfaces. The UV irradiation itself accounted for most of the decrease in 
viability.  
 
Biofilm inhibition: No long-lasting photocatalytic effect was observed by pre-
treating disks with UV. Equal amounts of CFUs (105 CFU ´ mL-1) were detected 
on both PVD and M Ti disks. However, a 70% reduction in adhered cells was 
observed on Ag disks compared with M Ti disks after 24 hours of incubation with 
S. aureus under flow conditions.  
 
Imprint method: In contrast, using this method, both the UV and/or the 
photocatalytic effect killed S. aureus cells on both PVD and M Ti surfaces after 60 
minutes. The Ag disks demonstrated an antimicrobial effect compared with 
control M Ti disks. 
 
Fluorescence: UV treatment (15 minutes) exhibited a photocatalytic effect, with a 
42% increase in dead cells on PVD disks compared with no UV treatment.  
 
In-situ bioluminescence: Both photocatalytic and UV demonstrated bactericidal 
effects after just 15 minutes of UV irradiation. An 82.7% decrease in bacterial 
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adhesion was observed on Ag disks compared with M Ti disks, when S. aureus 
Xen29 was cultured statically on the disks for 48 hours.  
  
Disk diffusion method: No zone of inhibition was detected with either the Ag disks 
or the M Ti disks. 
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4.2 Paper II 
Currently, the administration of antibiotics to patients is based on MIC 
determinations of the isolated microorganism. Evidence that biomaterial-
associated infections are caused by biofilm-forming bacteria with increased 
resistance to antibiotics implies the need for new diagnostic tools. A novel 
combination of the Calgary biofilm device (CBD) and a commercially available 
custom-made susceptibility microbroth dilution plate (Sensititre®) was developed 
and tested on clinical isolates isolated from osteomyelitis associated with 
percutaneous bone-anchored prostheses. The clinical strains were characterised 
based on their virulence in terms of biofilm-formation capacity and antimicrobial 
resistance.  
 
The analysis of the clinical outcome revealed four relapses, six implant extractions 
and five cases of re-infection during the study period. Treatment failure was 
determined for seven of eleven patients. Strains that caused infections for six of 
the seven treatment failures exhibited high MBECs against the antibiotics used 
for the respective treatment.  
 
One strain was characterised as a strong biofilm producer, six as moderate biofilm 
producers, three as weak biofilm producers and two as non-biofilm producers. 
This is the first time strains from osteomyelitis associated with percutaneous 
bone-anchored prostheses have been characterised based on their biofilm-
production abilities. All staphylococcal strains were positive for both icaA and 
icaD. All enterococcal strains had uniformly high MBEC values and higher 
MBEC/MIC ratios than staphylococcal strains. MIC determination for the strains 
for planktonic bacteria showed that 19% were resistant to the four most common 
antimicrobial agents: vancomycin, linezolid, ciprofloxacin and rifampin, whereas 
77% of the strains grown in biofilm were resistant to MBEC determination. 
 
A biofilm score of > 2 was assigned to 11 of 13 clinical strains, which correlated 
to higher MBEC/MIC ratios for vancomycin, linezolid, ciprofloxacin, ampicillin 
and rifampin.  
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4.3 Paper III 
Paper III investigates whether staphylococci isolated from human implant-related 
osteomyelitis have the ability to release EVs and whether the EVs elicit cytolysis, 
NF-kB activation and proinflammatory cytokine secretion in a THP-1 monocytic 
cell line. 
 
Nanoparticle tracking analysis and scanning electron microscopy revealed that all 
the staphylococcal strains released EVs. The number of EVs obtained from S. 
aureus strains was significantly higher than that from S. epidermidis strains. In 
contrast, however, there was no difference in the size of the EVs between the two 
species.  
 
As determined by Nucleocounter analysis, a significantly lower viability was 
detected for both concentrations (5 and 25 µg ´ mL-1) of S. aureus EVs compared 
with non-stimulated controls. The high dose of S. aureus EVs caused a 
significantly higher loss of viability in comparison with LTA. The two 
concentrations of S. aureus EVs demonstrated a significant decrease in viability in 
THP-1 cells in a dose-dependent manner. The high dose (25 µg ´ mL-1) of S. 
epidermidis EVs caused a significantly lower viability of THP-1 cells compared with 
the non-stimulated control group. No significant difference in Nucleocounter-
determined cell viability was detected between S. epidermidis EV and S. aureus EV 
treated groups.  
A significantly higher LDH in the supernatant (indicative of cytolysis) was 
measured with THP-1 cells stimulated with 5 and 25 µg ´ mL-1 of S. aureus EVs 
compared with negative and positive controls. EVs from S. aureus induced a 
significantly higher (» 2-fold) LDH release when compared with the equivalent 
concentrations of the S. epidermidis EVs. No statistically significant differences in 
LDH were observed between S. epidermidis EVs compared with negative control 
and LTA.  
The stimulation of THP-1 cells with S. epidermidis and S. aureus EVs resulted in 
higher gene expression of IL-8, MCP-1, MMP-9, IL-10 and IL-6 genes compared 
with unstimulated controls. Whereas TLR2 and TLR4 expressions were similar to 
those of controls, a 20- to 280-fold significantly higher expression of TLR3 was 
demonstrated for both S. epidermidis and S. aureus EVs compared with 
unstimulated control, irrespective of the EV concentration. TLR3 gene 
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expression was higher compared with control. DDIT4 gene expression was 
significantly higher for all EV-stimulated groups compared with LTA but not with 
unstimulated controls. All EV-stimulated groups, irrespective of species and 
concentrations, revealed a significantly lower Bcl-2 expression compared to both 
negative control and LTA.  
The secretion of IL-8 was significantly higher for groups treated with both 
concentrations of S. aureus and S. epidermidis EVs compared with unstimulated 
control and LTA. For S. epidermidis EV stimulation, a statistically significant dose-
dependent release of IL-8 by THP-1 cells was observed. All EV-treated groups 
elicited a significantly higher release of MCP-1, MMP-9 and IL-10 compared with 
the non-stimulated control group.  
 
Both S aureus and S. epidermidis EVs promoted higher NF-kB activation in THP-
1 blue cells compared with the unstimulated control at the three examined time 
points (6, 12 and 24 hours). Similar level of NF-kB activation was observed for 
the EV-stimulated groups and the HKLM positive control. Both S. aureus and S. 
epidermidis EVs were detected in the THP-1 cells, indicating the internalisation of 
EVs into cells. 
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4.4 Paper IV 
The effect of sub-inhibitory concentrations (0, 0.03, 0.06 µg ´  mL-1) of gentamicin 
(GEN) on the secretion of EVs by a clinical S. epidermidis strain was studied. A 
significant increase in the number of EVs per CFU was observed for EV2 (0.03 
µg ´ mL-1) and EV3 (0.06 µg ´ mL-1) compared with EV1 (0 µg ´ mL-1). In 
contrast, the nanoparticle tracking analysis did not reveal any significant 
differences in the mean sizes of the different EV groups. The total amount of 
protein was significantly higher for EV3 compared with EV1. 
 
The three EV types (EV1, EV2, EV3) isolated from the three sub-inhibitory 
culture conditions (0, 0.03, 0.06 µg ´ mL-1 respectively) were then added to 
cultures of the same strain to evaluate their effect on growth, viability and 
adhesion under increasing concentrations of GEN. When a dose of 5 µg ´ mL-1 
of EVs was added to the strain cultured without gentamicin (0 µg ´ mL-1 GEN), 
the area under the growth curve (AUC) did not differ for the three EV types. 
However, when gentamicin was present in the culture (0.03 µg ´ mL-1 GEN), the 
EV3 significantly reduced the total growth of the strain compared with the EV1 
and EV2 types. In the same way, with 0.06 µg ´ mL-1 GEN in the culture, the 
AUC of the strain was significantly lower upon stimulation with EV3 compared 
with Ctrl, EV1 and EV2. When culturing the strain with its MIC dose of GEN 
(0.12 µg ´ mL-1), bacterial growth was inhibited equally for all groups.  
The 60 µg ´ mL-1 dose of EVs significantly decreased the total growth of clinical 
S. epidermidis strain compared with the unstimulated Ctrl for all the gentamicin 
culture conditions (0, 0.03, 0.06, and 0.12 µg ´ mL-1 GEN). 
 
The generation time was the same for all EV groups and the Ctrl when the strain 
was cultured in 0 µg ´ mL-1 GEN and 0.03 µg ´ mL-1 GEN, when stimulated 
with 5 µg ´ mL-1. A decrease in generation time (faster doubling time) was 
detected for EV1 and EV3 compared with Ctrl for the 0.06 µg ´  mL-1 GEN culture 
condition. The generation time was instead increased (slower doubling time) by 
60 µg ´ mL-1 EV stimulation compared with Ctrl when the strain was cultured in 
0 µg ´ mL-1 GEN and 0.03 µg ´ mL-1 GEN. Since the strain did not grow in 0.06 
µg ´ mL-1 GEN, when stimulated with 60 µg ´ mL-1 of all EV types, the 
generation time was zero; while the strain divided every 76 minutes in the absence 
of GEN.  
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Stimulation with a 5 µg ´ mL-1 dose of EVs reduced adhesion (20-82%) in the 
absence and presence of gentamicin (0, 0.03 µg ´ mL-1), whereas the high dose 
(60 µg ´ mL-1) of EVs only reduced adhesion in the presence of gentamicin. 
 
EVs isolated from a biofilm-producing/GENR S. epidermidis strain were added to 
a non-biofilm-producing/GENS S. epidermidis recipient strain to examine whether 
they promoted antimicrobial tolerance and biofilm formation in the susceptible 
clinical strain. The overall growth (as measured by the AUC) of the clinical strain 
was significantly increased by adding 100 µg ´ mL-1 EVs of the biofilm-
producing/GENR strain compared with controls, with and without GEN and 
especially during exponential growth. In parallel, the generation time (at 
maximum growth rate) was shorter (8-33 minutes faster), as well as inhibited cell 
adhesion, compared with the Ctrl. The viability proportion, as measured by the 
live/dead staining, remained similar for both the EV and the Ctrl group.  
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5 DISCUSSION  
5.1 Diagnosis of biofilm infections  
The pathogenesis of many implant-associated infections is related to the presence 
of microorganisms growing as biofilms. Several measures have been taken to 
prevent these infections in the clinical setting, including strict hygienic rules, 
preoperative prophylactic antimicrobials, operating theatre environment 
conditions, and implant surface properties.141 The rates of e.g. prosthetic joint 
infections is estimated at about 1-2%, which is a large reduction compared with 
the introduction of arthroplasties in the 1960s when the infection rate was as high 
as 5-10%.169 In spite of this, the difficulty involved in the diagnosis and 
administration of the right treatment remains a challenge.  
Difficulties already occur with the sampling at the operating theatre. In some 
cases, bacteria are only identified until removal of the prosthesis.170 Biopsies might 
fail to sample the bacteria if the biopsies are not taken at the right place.171 In 
Paper II, which was a retrospective study, the sampling had not been taken 
systematically in accordance to a protocol regarding number of tissue biopsies, 
culturing of implant compartments or marrow blood samples [Paper II]. The 
inconsistency may of course jeopardise the accuracy of diagnosis, nevertheless, 
clinical history of the patients strongly suggested osteomyelitis. Equal to or more 
than 2/5 positive cultures was used for defining osteomyelitis. In addition, in 
most cases marrow blood samples were taken. The marrow blood samples were 
taken with a semi-invasive procedure unique for this type of implants. A small 
removable screw inside the fixture allows for the aspiration of marrow blood as 
well as minor tissue biopsies while the implant is still in place. Marrow culturing 
has been shown to have high diagnostic value.172 
The next problem to face is the fact that biofilm producing bacteria are hard to 
culture. The culture may be less reliable in biofilm-related infectious diseases due 
to inadequate sampling, too short incubation times, or inadequate choice of 
selective media.173 If technically possible, sonication of implant/implant parts 
shown to increase the sensitivity of bacterial detection.61,174,175 In a case study 
performed by our group, where an extracted fixture was sonicated before 
culturing, showing that the implant was positive for Escherichia coli (5 ´ 104 
CFU/implant) and Enterococcus faecalis (102 CFU/implant). Escherichia coli was the 
only species detected by standard tissue cultures performed by the clinical lab, 
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whereas E. faecalis was additionally detected after sonication (data not published). 
To distinguish between septic and aseptic loosening of prothesis it is suggested to 
combine several laboratory and histopathology markers of inflammation.41 
5.2 Characterisation of clinical isolates from chronic infections 
The phenotypic and genotypic biofilm properties of bacterial strains derived from 
osteomyelitis related to percutaneous osseointegrated orthopaedic implants have 
been analysed for the first time [Paper II]. Greater resistance to antimicrobials 
was demonstrated for bacteria growing within biofilms compared with their 
planktonic counterparts. This result is supported by other observations on 
staphylococcal strains derived from prosthetic joint infections176 and S. epidermidis 
strains from orthopaedic implant infections.177 Higher MBEC/MIC ratios were 
detected for biofilm-producing S. aureus and S. epidermidis compared with non-
biofilm producers [Paper II] which is in agreement with observations concerning 
prosthetic joint infections.176 The E. faecalis strains exhibited equally high MBEC 
than MIC values, although they were produced different amounts of slime 
(according to the CRA method). There are several ways for biofilms to increase 
their resistance to antimicrobials.69,178 The ability to produce slime appeared to 
play an important role in the contribution of high MBECs, since slime-producing 
strains showed significantly higher MBEC/MIC ratios than non-slime producing 
strains when examining all the strains [Paper II]. A report in line with our results 
show reduced bactericidal activity due to extracellular slime production of S. 
epidermidis in comparison to its biofilm-negative mutant.179 Another study 
investigating the importance of slime production in clinical strains of CoNS on 
antimicrobial activity showed that the presence of slime did not influence the 
activity of rifampin and very little influence on the activity of clindamycin 
however, vancomycin demonstrated a significant decrease in efficacy.180 A 
positive relationship was observed between the amount of isolated slime and the 
degree of resistance to vancomycin in a study on S. epidermidis isolates however 
not to rifampin.181 A study compared P. aeruginosa and S. aureus biofilms and their 
resistance to a cationic agent182. Interestingly, even though S. aureus biofilm was 
much weaker than the thicker and stronger P. aeruginosa biofilm, its formation lead 
to more drastic resistance than the resistance in P. aeruginosa biofilm. The 
extracellular polymeric substances played a significant role in resistance of P. 
aeruginosa while physiological changes in the biofilm cells were more likely 
contributing to the resistance of S. aureus.182 The importance of considering 
species-specific factors as well as molecular specific factors in biofilm resistance 
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patterns was emphasised.182 The mechanisms behind the effect of slime are not 
fully clear, but it has been suggested that it works as a diffusion barrier against 
small antimicrobial molecules.115 The fact that the biofilms in our study were 
relatively young (formed under 24 hours) it could implicate that other factors than 
slime also contribute to the elevated antimicrobial resistance.  
Two of the staphylococcal strains did not produce slime, but all of the 
staphylococcal strains possessed the icaA and icaD genes. The cell-cell adhesion 
function mediated by the ica locus appears to be conserved within the 
staphylococcal genus.167,183 However, it is not necessarily expressed. A study 
investigated the distribution of genes associated with biofilm formation and the 
expression of biofilm-forming phenotype of S. aureus and S. epidermidis strains 
derived from total-hips or total-knees infected arthroplasties.184 The study 
reported that all S. aureus strains and almost 70% of the S. epidermidis strains 
produced biofilm. Polysaccharide intercellular adhesin (PIA)-independent 
biofilms were produced by 27% of the biofilm-positive S. epidermidis strains, which 
were mediated by the accumulation-associated protein (Aap). However, 
icaADBC-independent biofilm mechanisms (deletion of the ica operon) have 
been described where biofilm-associated protein (Bap) was essential for both the 
initial adhesion and accumulation in S. aureus infection.185 It has been suggested 
that SarA plays an important role as a master regulator controlling both ica-
dependent and ica-independent biofilm mechanism.107 The co-expression of icaA 
and icaD is, however, needed for the full phenotypic expression, while the 
expression of only icaA induces low enzymatic activity.186 In our study, the 
expression of ica was not confirmed and only the presence of the icaA and icaD 
genes was determined. The ica locus is one of many potential targets for the 
prevention of biofilm-associated infections.  
Significant conclusions regarding MBECs in relation to clinical outcome could 
not be drawn due to the small sample size [Paper II]. Nevertheless, qualitative 
assessments indicate that the majority of treatment failures were associated with 
higher MBEC to the antibiotic administered to the patient. Only one patient 
experienced all three categories of complications (relapse, re-infection and 
extraction) and the infection was caused by a strong biofilm-producing E. faecalis 
strain. 
Another potential virulence trait of the clinical staphylococcal strains, the ability 
to produce EVs, has been explored [Paper III]. All the strains produced EVs 
irrespective of whether or not they were characterised as biofilm producing. The 
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effect of the EVs was tested on the monocytic THP-1 cell line, and on bacterial 
growth and adhesion under selective culture conditions [Paper III-IV].  
5.3 Mechanisms in the pathogenesis of percutaneous orthopaedic 
implant infections  
Patients with percutaneous orthopaedic implants are continuously exposed to the 
external skin microflora. Even though the cumulative risk of osteomyelitis over a 
10-year period is 20%, the osteomyelitis does not always lead to implant removal. 
The treatment retention rate for percutaneous orthopaedic implants is 30%.47 
Implant-associated infections have for long been treated as they were caused by 
planktonic bacteria. Infections caused by biofilm have unique characteristics, as 
described by Costerton and co-workers in the 1980s. The infection switches 
between dormant and acute periods. There may be an initial response to 
antimicrobials, but relapses are frequent.187 
5.3.1 The role of biofilms in infections 
Biofilm formation is a major virulence factor contributing to the chronic feature 
of many implant-associated infections. Antibiotic treatment alone is often 
inadequate to overcome these infections. Several reports on biofilm infections 
linked to medical devices or prosthesis have been published including orthopaedic 
implants188, catheters189, urinary catheters91, vascular prostheses190, prosthetic 
heart valves91 and cerebrospinal fluid shunts191, to mention some. In addition, 
biofilm formation is also common in infections not associated with foreign bodies 
such as chronic airway infections in cystic fibrosis patients192, chronic otitis 
media193, chronic sinusitis193 and chronic diabetes wound infections194. 
Characterisation of biofilm production abilities of isolated strains in the clinical 
setting is rarely performed when it comes to device-related biofilms, which could 
potentially help guide treatments. Conversely, biofilms are often confirmed and 
characterized during the diagnosis of non-device-related biofilm infections, for 
example in chronic wounds and cystic fibrosis.195 There are different methods 
that can be applied to characterise a biofilm infection.35 Fluorescence in situ 
hybridization (FISH) is a technique based on fluorescent probes that binds to 
parts of chromosome with a high degree of sequence complementarity and 
visualised by fluorescence microscopy. It can distinguish polymicrobial aggregates 
and allows visualization of the strains present in the biofilm and their specific 
special arrangement and localization in the host tissue.196 Polymerase chain 
 47 
reaction (PCR) is another frequently used method with high sensitivity, however, 
it does not distinguish between live and dead bacteria, nor if bacterial cells are 
aggregated or forming biofilms.   
There are studies reporting the in vitro characterisation of clinical isolates however, 
not for the purpose of guiding treatments. One study reported that out of 205 
clinical isolates from different chronic relapse infections, 126 strains formed 
biofilms in vitro although this study used the S. epidermidis ATCC12228 as an 
incorrect positive control strain for biofilm formation.197 Arciola and co-authors 
reported biofilm characteristics of strains isolated from catheter- and orthopaedic 
infections.79,186,198 In our small cohort, 11 out of 13 strains were biofilm producers 
according to in vitro measurements and most of them were classified as moderate 
or strong biofilm producers [Paper II]. The biofilm production was heterogenous 
across species and strains [Paper II]. Three of the staphylococcal strains exhibited 
low MBECs for some antimicrobials. It appeared that one of these strains was 
non-biofilm producer. Microtiter plate assay is a standard method for the 
determination of biofilm biomass. In our study we were lacking a non-slime 
producing S. aureus reference strain. We noticed the importance of having proper 
positive and negative control reference strains for each of the species when 
classifying the degree of biofilm production of the strains.  
5.3.2 EVs as a virulence factor: EV – bacterial cell interactions 
Bacteria are remarkable organisms that can adapt to extreme environmental 
conditions to ensure the survival of their species. Antimicrobial treatment induces 
selective pressure and makes bacteria be subjected to stress. The selective pressure 
might produce subpopulations that are better suited for causing disease (fitness 
advantage).199 In Paper IV, the effect of antimicrobial pressure, exerted by sub-
inhibitory concentrations of gentamicin, on vesiculation was evaluated. The sub-
inhibitory concentrations of gentamycin resulted in EVs of similar size and with 
higher protein content than those EVs isolated from control culture conditions. 
There is a risk that lysed cell debris contaminations contributed to the increased 
number EVs (according to NTA), however, when looking at the MIC dose of 
0.12 µg ´ mL-1 gentamycin (data not published) where more lysed cells are 
expected, the number of EVs was in fact much lower. Other studies have 
encountered the same concern. Studies on Pseudomonas aeruginosa vesiculation 
under antimicrobial pressure and aquatic bacteria under UV stress200 have 
similarly concluded higher vesiculation under pressure with higher OMV protein 
levels, which most likely reflect the vesiculation stimulation and not lysed 
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cells.201,202 A critical limitation of the present work on EVs is regarding the purity 
[Paper III-IV]. Additional step when concentrating the EV suspension by 
ultrafiltration was applied in Paper III using a 100 kDa hollow fiber membrane 
compared to only ultracentrifugation in Paper IV. The filter might have affected 
EV purity. In the research field of exosomes that are secreted by mammalian cells, 
effort has been spent on evaluating and optimizing exosome isolation techniques 
to optimise the purity.203-205 It is challenging to rapidly and efficiently isolate 
exosomes in large scale which also applies to the field of isolating bacterial 
vesicles. Ultracentrifugation is an expensive and time consuming method, does 
not result in high purity isolation and the vesicle yield is not very efficient206 
Factors affecting the EV isolation by ultracentrifugation are acceleration, type of 
rotor, time, viscosity of the sample, and storage.207-209 Density gradient 
ultracentrifugation and ultrafiltration such as gel chromatography increase the 
purity but disadvantages are its low yield and that fractions achieved are diluted 
and may require concentration of the sample.207 In our studies we were interested 
in investigating the cumulative effect of EVs, therefore fractioning was not 
performed. Further investigations on the effect of size and content of EVs 
separated by fractioning and how they differ is a natural next step to perform. 
The size of EVs varied between strains [Paper III] and one possible explanation 
for this observation may be that EVs can be synthesised and regulated in different 
ways.126 The total protein content may vary due to size of EVs and needs to be 
further investigated. In both Paper III and Paper IV, the total effect of all isolated 
EVs has been analyzed.  
OMVs derived from Gram-negative bacteria mediate the transfer and delivery of 
virulence factors to host immune cells and, the hypervesiculation of OMVs 
increases the tolerance to antimicrobials and increases the virulence of the 
strain.210 The results obtained in Paper III and IV confirmed these effects, 
staphylococcal EVs elicited cytotoxicity and cytokine release in monocytes and at 
the same time influenced antimicrobial tolerance and bacterial growth. 
OMVs have also been shown to be involved in the aggregation of bacterial cells 
and biofilm production,131,211,212 and sub-inhibitory concentrations of 
antimicrobials can enhance biofilm production in Pseudomonas aeruginosa.213,214 
Another study showed higher levels on drug-binding proteins in biofilm-derived 
OMVs compared to planktonic-derived OMVs.130 In our Paper IV, on the other 
hand, we noticed the opposite behaviour. The bacterial adhesion to culture plate 
mainly decreased with the addition of EVs. There may be several mechanisms for 
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this observed effect, but they were not evaluated in this study. This difference in 
adhesion between the EV-types may reflect different cargos, including different 
surface adhesins. This result goes in line with another recent study demonstrating 
decrease in adhesion to tissue culture plate with EVs present, which indicate that 
EVs adhere first to the surface making it more hydrophilic and not as accessible 
for the bacteria.215 These results are supported by our observations of a drastic 
decrease in adherence of S. epidermidis to glass after 24 hours incubation when 
treated with S. epidermidis EVs from another strain [Paper IV]. 
The dose of 5 µg ´  mL-1 EVs was perhaps too low to contribute to any measurable 
difference in total growth, while 60 µg ´  mL-1 EVs dose decreased the total growth 
after 18 hours for all cultures compared to control. This large decrease in total 
growth with the 60 µg ´ mL-1 EVs dose can be explained by the significant 
decrease in maximum growth rate, rather than changes in viability observed by 
fluorescence measurements. The proportions of live cells were generally higher 
than the proportion of dead cells in the fluorescence measurements. Therefore, 
addition of 60 µg ´ mL-1 EVs isolated from the clinical S. epidermidis strain allowed 
the cells to survive at MIC concentrations, by neither growing nor dying in the 
presence of gentamicin, but by decreasing the maximum growth rate, 
demonstrating tolerance to the antimicrobial agent.    
With the sub-inhibitory concentration of 0.06 µg ´ mL-1, no bacterial growth was 
detected when adding 60 µg ´ mL-1 EVs while growth was detected with 5 µg ´ 
mL-1 EV dose (except for EV3). This result indicates that the EVs contains 
different cargos of proteins, and that depending on the concentration of these 
cargos they could modulate the biological effects. Although the same total 
amount of protein was added to the S. epidermidis cultures (5 or 60 µg ´ mL-1), the 
total EV numbers varied between EV types (EV2 > EV3 > EV1) and some 
specific proteins could have been packed differently into the EVs due to the 
different antimicrobial pressure during their secretion. EV3 had the most amount 
of protein content and behaved differently than EV1 and EV2. For the EV3 group, 
either the higher number of EVs or the enrichment of certain proteins could have 
influenced the observed decreased effect on bacterial growth, maximum growth 
rate and live/dead ratio.   
Furthermore, we investigated if EVs (derived from GENR/biofilmpos strain) can 
alter the phenotype of a non-biofilm producing, gentamicin susceptible strain 
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GENS/biofilmneg). EVs cultured with the clinical GENS/biofilmneg S. epidermidis 
strain, promoted a significant increase in growth and faster generation time during 
exponential phase, as well as inhibited cell adhesion after 18 h compared to 
control. No shift in MIC was observed for the culture time tested, however, the 
EVs contributed to an increased tolerance to gentamicin and elicited a growth 
promoting effect. This growth promotion effect has been previously observed by 
our group in a different S. epidermidis strain and in S. aureus (data not published).  
Taken together, the results from Paper IV, suggest that the increase in number of 
EVs released by S. epidermidis when exposed to gentamicin might have important 
clinical implications in the treatment of patients with implant-associated 
infections caused by S. epidermidis. Furthermore, sub-optimal treatment 
concentrations might affect the cargo of released EVs, which can contribute to 
the total growth, cell division, and adhesion of S. epidermidis. EVs from the clinical 
GENS/biofilmneg S. epidermidis strain contributed to a decreased overall growth, 
slower planktonic cell division, and less adhesion when they were added in 
cultures of the same strain.  
5.3.3 EVs as a virulence factor: EV – host defence interactions 
We evaluated the effect of EVs derived from clinical osteomyelitis strains on 
THP-1 monocytic cell line. A dose-dependent reduction of THP-1 cell viability 
was observed when stimulated with S. aureus EVs [Paper III]. Although the high 
dose (25 µg ´ mL-1) of S. epidermidis EVs caused a significantly lower viability of 
THP-1 cells compared with the non-stimulated control group as judged by 
Nucleocounter assay, no significant difference in LDH release was detected for 
S. epidermidis EV groups compared to control. These findings go hand in hand 
with the fact that S. epidermidis is considered much less virulent than S. aureus.87 S. 
aureus is in the possession of a powerful set of toxins (a-Hemolysin (a-toxin), g-
hemolysin, leukotoxins and phenol-soluble modulins (PSMs))80,84,216, whereas S. 
epidermidis production of toxins is limited to phenol soluble modulins, having non-
cytolytic and cytolytic (PSMs) properties.87,217 
An interesting finding was the raised gene expression of DDIT4 and the reduced 
expression of Bcl-2, involved in the cellular response to hypoxia and stress218 and 
implicated in e.g. cell apoptosis and death219. Involvement of Bcl-2 regulated 
mechanisms in bacteria-induced cell apoptosis have been suggested previously.84 
However, to our knowledge, an enhanced expression of DDIT4 as an effect of 
bacteria/bacterial products has not previously been reported in relation to host 
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cell death. Taken together, our findings suggest that not only S. aureus EVs but 
also S. epidermidis EVs are agonists of cell injury and death. These observations 
provide strong motivation to further studies on this aspect of microbe-host cell 
interactions. 
Own previous studies have shown that opsonized live S. epidermidis promote the 
expression of proinflammatory cytokines and production of reactive oxygen 
species in human monocytes in vitro.220 Moreover, S. epidermidis elicit strong 
recruitment of PMNs, cell death and increased gene expression of TNF-a, IL-6, 
IL-8, TLR2 and elastase when administered at titanium implants in vivo.221 Since 
S. epidermidis presents a less aggressive and more chronic nature with its 
pathogenicity mainly related to biofilm formation81,222, it was interesting to 
observe a similar degree of NF-kB activation, gene expression, cytokine 
expression and cytokine secretion, attributed to S. epidermidis and S. aureus EVs, 
indicating a similar ability to activate a pro-inflammatory state in monocytes, at 
least during in vitro conditions.  
Among the Pattern recognition receptors (PRR) expressed by cells of the innate 
immune system, the cell membrane bound Toll-like receptors identify molecular 
patterns associated with microbial pathogens and constituents released in 
conjunction with cell death223 The present study explored if THP-1 cells 
expressed three TLRs (TLR2, TLR3, TLR4), implicated in NF-kB activation and 
cytokine secretion induced by gram-positive and Gram-negative 
bacteria/bacterial products. For example, LTA from S. aureus induces PMN 
secretion of IL-8 via CD14 and TLR2 and nuclear factor-kB activation.224 After 
24 hours culture of THP-1 cells, only TLR3 was significantly upregulated by 
interaction with S. aureus and S. epidermidis EVs. TLR3 recognizes double-stranded 
RNA usually carried by some viruses.225 An important continuation of the present 
experiments is to determine the early temporal changes of EV-induced expression 
of TLRs in relation to the pathways of apoptosis and NF-kB /cytokines. 
Proteomic studies have revealed that the S. aureus EVs contain lipids, proteins 
(toxins and adhesion molecules), b-lactamase, and other tissue destructive 
enzymes.132,138,226 To our knowledge, similar studies of S. epidermidis EVs have not 
yet been performed and needs to be further investigated.  LTA (5 µg ´ mL-1) 
served as positive control, however, its response turned out to be weak. Another 
well-known inflammatory inducer, frequently used as positive control is 
lipopolysaccharide227 (LPS), which is found in the Gram-negative bacterial cell 
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membrane, but since the EVs used were from Gram-positive origin, LTA was 
chosen.  
Monocytes are one of the first cells to arrive to the infection site and are therefore 
an interesting model cell to use. Among the advantages of using a cell line is the 
reduced number of variables that affect the outcome. However, if EVs elicit 
similar effects on primary cells such as PMNs needs to be further investigated, as 
well as analysing several time-points other than 24 hours as endpoints for the 
analysis of cytokine release. The EV sample size was small, however, we have 
obtained all available samples originating from patients with percutaneous 
orthopaedic implants diagnosed with osteomyelitis. The relationship between 
biofilm production abilities and the number of released vesicles, their cytolytic 
and cytokine secretory effects could not be ruled out. Larger patient cohort with 
infections associated with total hip replacements is an ongoing study which will 
allow these comparisons.  
5.4 Novel diagnostic tools and strategies for infection control  
5.4.1 Evaluation of antimicrobial surfaces 
There are several variables that may influence the risk of implant-associated 
infection making the assessment of the clinical efficacy of orthopaedic implants 
an extremely difficult task. As mentioned above, apart from strict hygienic rules, 
preoperative prophylactic antimicrobials, operating theatre environment 
conditions and predisposing factors of the patient, the actual implant material 
surface plays a major role. A variety of categories of anti-infective approaches 
have been implemented to achieve biomaterials with antimicrobial properties and 
new additional approaches are rapidly advancing. Different strategies are needed 
depending on the application which, in addition, means that appropriate 
evaluation methods are also needed and adapted to the material’s mode of action.    
Factors affecting the end point results when evaluating antimicrobial surfaces 
with different methods are culture media, rinsing steps, bacterial inoculum size228, 
sterilization method229,230. Different methodological setups were evaluated with 
two different test surfaces (Ag and PVD) and control (Ti) surface [Paper I]. The 
test surfaces performed differently depending on the evaluation method.  
The disk diffusion method is a common method for evaluating antimicrobial 
release of a test surface. The size of inhibition zone is a function of the ability for 
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the antibiotic to diffuse, the susceptibility of the strain, and its growth rate under 
standard experimental conditions (medium, agar, thickness, incubation 
temperature and disk content). The zone of inhibition may depend on the rate of 
diffusion of antimicrobials though the agar.231 In contrast, the imprint method, 
showed an antimicrobial effect of the Ag surface, which confirmed the contact-
killing mode of action (and not the release mode of action). The UV contributed 
to the killing of the bacteria and the photocatalytic activity was mostly short.  
In vitro testing is the first step for evaluating antimicrobial surfaces, the next step 
towards clinical use is to test the surface in vivo using an animal model. The 
presence of the host immune defence is a very important additional factor in vivo, 
which will contribute to the final outcome. In vitro testing cannot predict which 
host proteins will adhere to the surface at the moment of implantation that will 
serve as a substrate for host cells and microorganisms. A difference in bacterial 
adhesion may be obtained depending on the adsorbed proteins.232  
A critical limitation of the Paper I is the limited amount of test surfaces. More 
than two different modes of action could have been evaluated simultaneously to 
better show the difference between the in vitro tests.  
The final answer whether a prosthetic surface property conveys an antimicrobial 
effect requires clinical trials. As previously discussed, a prerequisite for implanted 
orthopaedic prostheses is the development of a mechanically stable interface 
between the bone and the prosthesis. This interface is the scene of multiple 
biological events, ranging from initial inflammation to bone formation and 
remodeling.233,234 The presently studied amputation prostheses are built upon the 
principle of osseointegration, the need for stable interfaces between implant, bone 
and soft tissues and between the different components of the implant system in 
order to enable an efficient load transfer, the sealing of the interior from the 
exterior and the avoidance of wear and abrasion.13 Results demonstrate 
osseointegrated implants, 92% survival and improved function and quality of life 
after 2 years-follow-up compared to conditions before surgery.16,235,236  
It is hypothesised that unless proper osseointegration is achieved or if 
osseointegration is lost, the possibilities for microorganisms to adhere to and 
colonize the implant surface is increased.49 Therefore, novel in vitro documented 
antibacterial surfaces must also be assessed with respect to their ability to become 
integrated in bone in experimental in vivo conditions.237 In addition, such concepts 
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should be subjected to a step-wise introduction into the clinical reality, similar to 
the principle suggested for the introduction of novel arthroplasties.238 
5.4.2 Biofilm susceptibility testing  
Prescribing antibiotic regimens that target acute infection when treating a chronic 
biofilm infection may be devastating since the regimen may potentially may not 
heal the infection and further induce resistance mechanisms. MIC determination 
is the standard procedure when treatment is administered to the patient. As it has 
been observed in Paper II, bacteria living in biofilms elicit >1000 higher resistance 
to antimicrobials than their planktonic counterpart, and a combination of 
antimicrobials are needed together with long treatment periods. The MIC and 
MBEC values differed for vancomycin, linezolid, ciprofloxacin and rifampin, the 
antibiotics most commonly used in the treatment of orthopaedic implant 
infections [Paper II]. The fact that the 13 strains exhibited much higher resistance 
to these antibiotics when adhered to the CBD implies their low efficacy in chronic 
biofilm infections associated to implants. There is a need for a new tool to better 
predict antimicrobial susceptibilities. The combination of CBD and Sensititre 
antibiotic plate tested in Paper II is a good candidate for this purpose. The method 
is relatively cost efficient, easy to standardize and the results are produced within 
5 days.  This time is extremely short considering the long average antibiotic 
treatment length of these patients (4 months) [Paper II].    
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6 SUMMARY AND CONCLUSIONS 
- Several methods, tailored to the specific surface modification 
and antimicrobial mode of action, should be applied to provide 
valuable complementary information when evaluating 
antimicrobial surfaces with prophylactic and treatment effects 
against planktonic and biofilm bacteria. These methods can be 
employed to evaluate the first in vitro “proof-of-concept” in the 
development of new antimicrobial approaches.  
 
- Most of the staphylococcal and enterococcal clinical strains 
isolated from patients with osteomyelitis associated with 
percutaneous bone-anchored implants had the ability to 
produce biofilms. In general, the biofilms required higher 
antimicrobial concentrations compared with non-biofilm 
producers. The same strain when grown as biofilms exhibited a 
significant increase in antimicrobial resistance compared with 
when it was grown planktonically.  
 
- The majority of treatment failures were linked to high biofilm 
resistance towards the most commonly used antimicrobial 
agents in the clinic. The hereby-described diagnostic method for 
biofilm susceptibility testing may be useful to guide 
antimicrobial treatment decisions in orthopaedic implant-
associated infection. 
 
- The S. aureus strains produced significantly more EVs than the 
S. epidermidis strains. Both S. aureus- and S. epidermidis-derived EVs 
upregulated Toll-like receptor 3 (TLR3) gene expression, 
activated NF-kB, and promoted the gene expression and 
secretion of IL-8, MCP-1, MMP-9 and IL-10. Both EV types 
were internalized by a proportion of the THP-1 cells. Whereas 
EVs from both staphylococcal species upregulated the pro-
apoptotic DNA-damage-inducible transcript 4 (DDIT4) and 
down-regulated the anti-apoptotic B-cell lymphoma 2 (Bcl-2) 
genes, cytolysis was preferentially induced in S. aureus EV-
stimulated cells.  
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- Sub-inhibitory concentrations of antimicrobial agents 
stimulated Staphylococcus epidermidis to secrete higher number of 
EVs with more protein content, which strongly affected 
bacterial cell adherence and growth. Treating orthopaedic 
implant-associated infection with sub-inhibitory concentrations 
of antimicrobial agents could be promoting EV-release with 
specific virulence traits. 
 
It is concluded that, isolates from implant-associated infection reveal multiple 
virulence traits relevant for understanding and treating these infections. This 
thesis proposes EVs as a novel pathogenic mechanism of biomaterial-associated 
infection, requiring further research focus. 
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7 FUTURE PERSPECTIVES 
Major efforts are focused on the prevention, diagnosis and treatment of 
implant-associated infections. Strategies to minimise the occurrence of 
these infections requires increased understanding of both material-
related and biological factors. The findings of this thesis demonstrate 
potential virulence traits of clinical isolates from implant-related 
osteomyelitis. To further investigate their role in pathogenesis of these 
infections it would be of interest to explore the following: 
 
- The potential of the combination of Calgary biofilm device and 
Sensititre susceptibility plate in a prospective study for MBEC-
guided treatment. 
- Further studies on the effect of EVs derived from clinical 
osteomyelitis isolates on primary cells. By e.g. blocking of 
specific cell surface receptors and inhibition of internalisation 
processes, further understanding of the EV-host cell 
interactions will be provided. Further, the effects in vivo of the 
EVs will be of great interest. 
- Molecular analysis of fraction isolated EVs (Proteomic, 
genomics, and RNA-sequencing). 
- In vitro transfer experiments to ascertain if resistance genes can 
be horizontally transferred via EVs. 
- The virulence effect of EVs on host cells when compared to its 
own parental bacterial cell (heat-inactivated). 
- With a greater number of strains, evaluate if the biofilm 
formation degree associates with a particular EV-content or 
phenotype. 
- In vivo proof of EV involvement in the pathogenesis of 
biomaterial-associated infection, by the isolation of 
staphylococcal EVs in infected tissue/implant samples from 
patients. 
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